Pilot editing system based on PERV reverse transcriptase

By using PERV-NC fusion RNase H structure deleted multi-mutant PERV-RT instead of MMLV-RT in the PE2 editor, the problem of low editing efficiency of mammalian cells in the prior art is solved, and a more efficient pilot editing effect is achieved.

CN118995664AActive Publication Date: 2024-11-22JIANGXI AGRICULTURAL UNIVERSITY +1

Patent Information

Application Number
CN202410635868.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-21
Publication Date
2024-11-22
Estimated Expiration
2044-05-21

AI Technical Summary

Technical Problem

Existing pilot editing systems are less efficient in mammalian cells, especially when using other types of reverse transcriptases, which are significantly less efficient than PE2 systems, and the nucleocapsid protein is not fused with reverse transcriptase in mammalian cells. It can significantly improve editing efficiency.

Method used

PERV-RT, which uses PERV-NC fusion RNase H structure to delete and carry multiple mutation sites, replaces MMLV-RT in the PE2 editor to improve the efficiency of pilot editing in mammals.

Benefits of technology

The editing efficiency in mammalian cells was significantly improved. The epPE editor from PERV-RT-derived is more efficient than the PE2c-Puro editor from mouse RT, and the epPE editor from different types of PERV-RT in different cell lines. Different performances, but higher overall performance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004852753160000191
    Figure BDA0004852753160000191
  • Figure BDA0004852753160000261
    Figure BDA0004852753160000261
  • Figure BDA0004852753160000262
    Figure BDA0004852753160000262
Patent Text Reader

Abstract

The invention relates to the field of gene engineering. Specifically, the invention relates to a PERV reverse transcriptase-based pilot editing system and a gene editing method through the system. More specifically, the present invention provides: 1, a PERV-RT pilot editing system using PERV-NC fusion RNase H structure deletion and carrying a plurality of mutation sites; 2, a pegRNA (tCsy4-pegRNA) fused with the truncated type Csy4, and a pegRNA (tCsy4-pegRNA) fused with the truncated type Csy4; 3, one or more small molecule compounds for treating cells and combinations thereof; therefore, the efficiency of pilot editing in mammals is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of genetic engineering. Specifically, the present invention relates to a lead editing system based on PERV reverse transcriptase and a method for gene editing using the system. Background of the Invention

[0003] Prime Editing (PE) is a new gene editing technology that has emerged in recent years. It can achieve various types of editing such as point mutation, insertion, deletion, and replacement without generating double-strand breaks in DNA. It overcomes the main shortcomings of current CRISPR / Cas9 and single-base editing technologies and is currently the most accurate genome editing technology. The PE editing system consists of a PE editor and a prime editing guide RNA (pegRNA and / or ngRNA). Among them, the PE editor is the most important component of prime editing. The PE editor is a fusion of the Cas9 single nickase (nCas9 H840A) and the reverse transcriptase (RT). The currently more efficient and widely used PE2 and its improved version PEmax editor use the reverse transcriptase (MMLV-RT) of the mouse Moloney murine leukemia virus carrying five mutations: D200N, L603W, T330P, T306K, and W313F.

[0004] Some teams have used other types of RT for lead editing, but their efficiency is lower or significantly lower than PE2. Other reports have shown that the fusion of nucleocapsid protein (NC) and RT can help improve the efficiency of lead editing. The fusion of MMLV's nucleocapsid protein (NC) with MMLV-RT (MMLV-RT (ΔRNase H)) that deletes the RNase H structure has developed an efficiency-enhanced PE editor: ePPE. However, reports to date have shown that ePPE only significantly improves editing efficiency in plant cells, but not in mammalian cells.

[0005] There is still a need in the art for efficient prime editing systems, particularly prime editing systems that can perform efficient editing in mammalian cells. Brief description of the invention

[0007] The present invention uses PERV-NC fused with RNase H structure deletion and carrying multiple mutation sites to replace MMLV-RT in the PE2 editor to improve the efficiency of lead editing in mammals. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] Figure 1 . Shows the amino acid sequence alignment of MMLV-RT (ΔRNase H), PERV-AC-RT (ΔRNase H) and PERV-B-RT (ΔRNase H).

[0010] Figure 2 . Schematic diagram of the vector of the PERV reverse transcriptase editor showing different NCBI sequences of the present invention.

[0011] Figure 3 .Shows the editing efficiency of PE2c-Puro, epPE-B-M3Δ-Puro, and epPE-B-M4Δ*-Puro editors in the BFP reporter cell line.

[0012] Figure 4 .Shows the editing efficiency of PE2c-Puro and epPE-M3Δ-Puro editors in primary PFFs.

[0013] Figure 5 . Shown are the editing efficiencies of PE2c-Puro and epPE-AC-M3Δ-Puro editors in HEK293T, canine fetal fibroblasts (DFF), and sheep fetal fibroblasts (SFF) cells.

[0014] Figure 6 .Shows a schematic diagram of the vector based on different Bama Xiang pig PERV reverse transcriptase editors of the present invention.

[0015] Figure 7 .Shows the editing activity of the pPE editor of Bama Xiang pig PERV reverse transcriptase containing 4 point mutations and wild type in the BFP reporter gene cell line.

[0016] Figure 8 .Shows the editing efficiency of the Bama Xiang pig PERV reverse transcriptase pPE editor containing 4 point mutations in PFF.

[0017] Fig. 9 .Shows the editing efficiency of the Bama Xiang pig PERV reverse transcriptase pPE editor containing 4 point mutations in HEK293T, canine fetal fibroblasts (DFF), and sheep fetal fibroblasts (SFF).

[0018] Fig.10 .Shows the editing efficiency of Bama Xiang pig PERV reverse transcriptase epPE editor in PFF based on 4 point mutations.

[0019] Fig.11 .Shows the editing efficiency of Bama Xiang pig PERV reverse transcriptase epPE editor based on 4 point mutations in HEK293T, canine fetal fibroblasts (DFF), and sheep fetal fibroblasts (SFF).

[0020] Fig.12.Shows the editing efficiency of the Bama Xiang pig PERV reverse transcriptase pPE editor containing 1-6 point mutations when co-transfected with a fluorescent reporter gene in HEK293T cells.

[0021] Fig.13 .Shows the editing efficiency of Bama Xiang pig PERV reverse transcriptase pPE editor in HEK293T cells based on M5.1 superimposed with different point mutations.

[0022] Fig.14 .Shows the editing efficiency of Bama Xiang pig PERV reverse transcriptase pPE editor in HEK293T cells based on 7 point mutations.

[0023] Fig.15 .Shows the editing efficiency of the epPE editor based on 7 point mutations of Bama Xiang pig PERV reverse transcriptase in HEK293T cells.

[0024] Fig.16 .Shows the efficiency of the epPE editor based on 7 point mutations of Bama Xiang pig PERV reverse transcriptase compared with PEmax, PE6c and PE6d.

[0025] Fig.17 .Show that Csy4 and tCsy4-pegRNA improve the editing efficiency of PE editor.

[0026] Fig.18 .Show that small molecule compounds improve the editing efficiency of PE editors. DETAILED DESCRIPTION OF THE INVENTION

[0028] I. Definition

[0029] In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, immunology related terms and laboratory operation procedures used herein are terms and routine procedures widely used in the corresponding fields. For example, the standard recombinant DNA and molecular cloning techniques used in the present invention are well known to those skilled in the art and are more fully described in the following documents: Sambrook, J., Fritsch, EF and Maniatis, T., Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter referred to as "Sambrook"). At the same time, in order to better understand the present invention, the definitions and explanations of the relevant terms are provided below.

[0030] As used herein, the term "and / or" encompasses all combinations of items connected by the term, and each combination should be considered to have been listed separately herein. For example, "A and / or B" encompasses "A," "A and B," and "B." For example, "A, B, and / or C" encompasses "A," "B," "C," "A and B," "A and C," "B and C," and "A and B and C."

[0031] When the term "comprising" is used herein to describe a protein or nucleic acid sequence, the protein or nucleic acid may consist of the sequence, or may have additional amino acids or nucleotides at one or both ends of the protein or nucleic acid, but still have the activity described in the present invention. In addition, it is clear to those skilled in the art that the methionine encoded by the start codon at the N-terminus of the polypeptide may be retained in certain practical situations (for example, when expressed in a specific expression system), but it does not substantially affect the function of the polypeptide. Therefore, when describing a specific polypeptide amino acid sequence in the specification and claims of this application, although it may not contain a methionine encoded by a start codon at the N-terminus, a sequence containing the methionine is also covered at this time, and accordingly, its encoding nucleotide sequence may also contain a start codon; and vice versa.

[0032] "Genome" as used herein encompasses not only the chromosomal DNA present in the cell nucleus, but also the organellar DNA present in subcellular components of the cell (eg, mitochondria, plastids).

[0033] As used herein, "organism" includes any organism suitable for genome editing, preferably a eukaryotic organism. Examples of organisms include, but are not limited to, mammals such as humans, mice, rats, monkeys, dogs, pigs, sheep, cattle, cats; poultry such as chickens, ducks, geese; plants including monocots and dicots, such as rice, corn, wheat, sorghum, barley, soybeans, peanuts, Arabidopsis, etc.

[0034] "Genetically modified organism" means an organism that contains exogenous polynucleotides or modified genes or expression control sequences in its genome. For example, exogenous polynucleotides can be stably integrated into the genome of the organism and inherited for consecutive generations. Exogenous polynucleotides can be integrated into the genome alone or as part of a recombinant DNA construct. The modified gene or expression control sequence is one in which the gene or expression control sequence contains one or more nucleotide substitutions, deletions, and additions in the genome of the organism.

[0035] "Exogenous" with respect to a sequence refers to a sequence that is from a foreign species, or, if from the same species, a sequence that has been significantly altered in composition and / or locus from its native form through deliberate human intervention.

[0036] "Polynucleotide", "nucleic acid sequence", "nucleotide sequence" or "nucleic acid fragment" are used interchangeably and are single-stranded or double-stranded RNA or DNA polymers, optionally containing synthetic, non-natural or altered nucleotide bases. Nucleotides are referred to by their single letter names as follows: "A" is adenosine or deoxyadenosine (RNA or DNA, respectively), "C" represents cytidine or deoxycytidine, "G" represents guanosine or deoxyguanosine, "U" represents uridine, "T" represents deoxythymidine, "R" represents purine (A or G), "Y" represents pyrimidine (C or T), "K" represents G or T, "H" represents A or C or T, "D" represents A, T or G, "I" represents inosine, and "N" represents any nucleotide. Although nucleotide sequences herein may be represented as DNA sequences (including T), when RNA is referred to, the corresponding RNA sequence can be easily determined by a skilled artisan (i.e., replacing T with U).

[0037] "Polypeptide", "peptide", and "protein" are used interchangeably herein to refer to polymers of amino acid residues. The term applies to amino acid polymers in which one or more amino acid residues are artificial chemical analogs of the corresponding naturally occurring amino acids, as well as to naturally occurring amino acid polymers. The terms "polypeptide", "peptide", "amino acid sequence" and "protein" may also include modified forms, including but not limited to glycosylation, lipid attachment, sulfation, gamma carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation.

[0038] Sequence "identity" has a meaning recognized in the art, and the percentage of sequence identity between two nucleic acid or polypeptide molecules or regions can be calculated using published techniques. Sequence identity can be measured along the full length of a polynucleotide or polypeptide or along a region of the molecule. (See, for example: Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). Although there are many methods to measure the identity between two polynucleotides or polypeptides, the term "identity" is well known to those of skill (Carrillo, H. & Lipman, D., SIAM J Applied Math 48: 1073 (1988)).

[0039] As used herein, "amino acid position references SEQ ID NO: x" (SEQ ID NO: x is a specific sequence listed herein) means that the position number of the specific amino acid being described is the position number of the amino acid corresponding to the amino acid on SEQ ID NO: x. The correspondence of amino acids in different sequences can be determined according to sequence alignment methods known in the art. For example, amino acid correspondence can be determined by the online alignment tool of EMBL-EBI (https: / / www.ebi.ac.uk / Tools / psa / ), where two sequences can be aligned using the Needleman-Wunsch algorithm using default parameters. For example, if the alanine at position 360 from the N-terminus of a polypeptide is aligned with the amino acid at position 365 of SEQ ID NO: x in a sequence alignment, then the alanine amino acid in the polypeptide may also be described herein as "alanine at position 365 of the polypeptide, the amino acid position references SEQ ID NO: x".

[0040] As used herein, "expression construct" refers to a vector such as a recombinant vector suitable for expressing a nucleotide sequence of interest in an organism. "Expression" refers to the production of a functional product. For example, the expression of a nucleotide sequence can refer to the transcription of the nucleotide sequence (such as transcription to generate mRNA or functional RNA) and / or the translation of RNA into a precursor or mature protein.

[0041] The "expression construct" of the present invention can be a linear nucleic acid fragment, a circular plasmid, a viral vector, or, in some embodiments, can be a translatable RNA (such as mRNA), for example, RNA generated by in vitro transcription. For use in mammals such as humans, the expression construct is preferably a viral vector, such as an adeno-associated virus (AAV), a lentivirus, an adenoviral vector, and most preferably an AAV vector.

[0042] An "expression construct" of the present invention may comprise regulatory sequences and a nucleotide sequence of interest from different sources, or regulatory sequences and a nucleotide sequence of interest from the same source but arranged in a manner different from that normally found in nature.

[0043] "Promoter" refers to a nucleic acid fragment that can control the transcription of another nucleic acid fragment. In some embodiments of the present invention, a promoter is a promoter that can control the transcription of a gene in a cell, whether or not it is derived from the cell. A promoter can be a constitutive promoter or a tissue-specific promoter or a developmentally regulated promoter or an inducible promoter.

[0044] Examples of promoters include, but are not limited to, polymerase pol I, pol II, or pol III promoters. Examples of pol I promoters include chicken RNA pol I promoters. Examples of pol II promoters include, but are not limited to, cytomegalovirus immediate early (CMV) promoters, Rous sarcoma virus long terminal repeat (RSV-LTR) promoters, and simian virus 40 (SV40) immediate early promoters. Examples of pol III promoters include U6, U3, and H1 promoters. Inducible promoters such as metallothionein promoters can be used. Other examples of promoters include T7 phage promoters, T3 phage promoters, β-galactosidase promoters, and Sp6 phage promoters. When used for plants, the promoter can be a cauliflower mosaic virus 35S promoter, a corn Ubi-1 promoter, a wheat U6 promoter, a rice U3 promoter, a corn U3 promoter, or a rice actin promoter.

[0045] "Introducing" a nucleic acid molecule (e.g., a plasmid, a linear nucleic acid fragment, RNA, etc.) or a protein into an organism refers to transforming an organism cell with the nucleic acid or protein so that the nucleic acid or protein can function in the cell. "Transformation" as used in the present invention includes stable transformation and transient transformation. "Stable transformation" refers to the introduction of an exogenous nucleotide sequence into a genome, resulting in stable inheritance of the exogenous gene. Once stably transformed, the exogenous nucleic acid sequence is stably integrated into the genome of the organism and any successive generations thereof. "Transient transformation" refers to the introduction of a nucleic acid molecule or protein into a cell, performing a function without stable inheritance of the exogenous gene. In transient transformation, the exogenous nucleic acid sequence is not integrated into the genome.

[0046] "Trait" refers to a physiological, morphological, biochemical, or physical characteristic of a cell or organism.

[0047] 2. Reverse transcriptase from PERV and its variants

[0048] In one aspect, the present invention provides a reverse transcriptase from porcine endogenous retrovirus (PERV) or a functional variant thereof. The reverse transcriptase has a reverse transcription activity of generating a complementary DNA chain using a single-stranded RNA as a template, while its functional variant substantially retains or has an enhanced reverse transcription activity. The reverse transcriptase from PERV or a functional variant thereof described in the present invention can be used for lead editing, particularly for lead editing in mammalian cells.

[0049] In some embodiments, the reverse transcriptase from PERV (also referred to herein as PERV reverse transcriptase) is from type A, type B, or type C PERV, or from a recombinant of a different type of PERV, such as a type A / C PERV recombinant.

[0050] In some embodiments, the PERV is a PERV isolated from Bama Xiang pig. In some embodiments, the PERV is isolated from other breeds of pigs.

[0051] In some embodiments, the PERV reverse transcriptase or a functional variant thereof comprises an amino acid sequence of one of SEQ ID NOs: 1-5 or an amino acid sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or even 100% sequence identity with one of SEQ ID NOs: 1-5.

[0052] In some embodiments, the functional variant of the PERV reverse transcriptase lacks the RNase H domain. The RNase H domain of the PERV reverse transcriptase, for example, comprises an amino acid sequence corresponding to about position 514 to about position 616 of SEQ ID NO:1.

[0053] In some embodiments, the functional variant of the PERV reverse transcriptase comprises an amino acid substitution at one or more positions selected from position 63, 199, 222, 305, 312, 329, 330, 331, 332, 408, or 602.

[0054] When referring to the amino acid position of PERV reverse transcriptase or a functional variant thereof herein, the amino acid position refers to SEQ ID NO:5.

[0055] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, and 312. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, and W312F.

[0056] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, and L602W.

[0057] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, 329, 330, 331, and 332. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, E329P, K330G, G331T, and E332C.

[0058] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, 329, 330, 331, 332, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, E329P, K330G, G331T, E332C, and L602W.

[0059] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 222, 305, 312, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, V222A, T305K, W312F, and L602W.

[0060] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 63, 199, 222, 305, 312, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions Y63R, D199N, V222A, T305K, W312F, and L602W.

[0061] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 222, 305, 312, 408, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, V222A, T305K, W312F, C408R, and L602W.

[0062] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 63, 199, 222, 305, 312, 408, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions Y63R, D199N, V222A, T305K, W312F, C408R, and L602W.

[0063] In some specific embodiments, the functional variant of the PERV reverse transcriptase comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 6 (corresponding to AC-RT-M0Δ), SEQ ID NO: 7 (corresponding to AC-RT-M3Δ), SEQ ID NO: 8 (corresponding to AC-RT-M4Δ*), SEQ ID NO: 9 (corresponding to B-RT-M0Δ), SEQ ID NO: 10 (corresponding to B-RT-M3Δ), SEQ ID NO: 11 (corresponding to B-RT-M4Δ*), and SEQ ID NO: 12 (corresponding to bmx-A-RT-M4), SEQ ID NO: 13 (corresponding to bmx-B-RT-M4), SEQ ID NO: 14 (corresponding to bmx-C-RT-M4), SEQ ID NO: 15 (corresponding to bmx-A-RT-M3Δ), SEQ ID NO: 16 (corresponding to bmx-B-RT-M3Δ), SEQ ID NO: 17 (corresponding to bmx-C-RT-M3Δ), SEQ ID NO: 18 (corresponding to bmx-B-RT-M3Δ), SEQ ID NO: 19 (corresponding to bmx-C-RT-M3Δ), SEQ ID NO: 20 NO:40 (corresponding to bmx-C-RT-M5.1), SEQ ID NO:41 (corresponding to bmx-C-RT-M5.1+Y63R), SEQ ID NO:42 (corresponding to bmx-C-RT-M5.1+C408R), SEQ ID NO:43 (corresponding to bmx-C-RT-M7) and SEQ ID NO:44 (corresponding to bmx-C-RT-M7Δ).

[0064] In another aspect, the present invention provides use of the reverse transcriptase from PERV or a functional variant thereof of the present invention for lead editing, in particular for use in lead editing in mammalian cells.

[0065] The "mammal" described herein includes but is not limited to humans, mice, rats, monkeys, dogs, pigs, sheep, cows, cats, etc. In some preferred embodiments, the mammal is a pig. In some preferred embodiments, the mammal is a human.

[0066] 3. Primer editing system based on reverse transcriptase from PERV

[0067] In one aspect, the present invention relates to a lead editing system for targeted modification of a genomic DNA sequence of an organism, comprising:

[0068] i) a CRISPR nuclease such as a CRISPR nickase and / or an expression construct comprising a nucleotide sequence encoding said CRISPR nuclease such as a CRISPR nickase, and a PERV reverse transcriptase or a functional variant thereof and / or an expression construct comprising a nucleotide sequence encoding said PERV reverse transcriptase or a functional variant thereof; and / or

[0069] ii) at least one pegRNA and / or an expression construct containing a nucleotide sequence encoding said at least one pegRNA.

[0070] In some embodiments, the at least one pegRNA comprises, from 5' to 3' direction, a leader sequence, a scaffold sequence, a reverse transcription template (RTT) sequence, and a primer binding site (PBS) sequence.

[0071] In some embodiments, the CRISPR nuclease, such as a CRISPR nickase, and the PERV reverse transcriptase or a functional variant thereof form a fusion protein.

[0072] In one aspect, the present invention relates to a lead editing system for targeted modification of a genomic DNA sequence of an organism, comprising:

[0073] i) a lead editing fusion protein and / or an expression construct containing a nucleotide sequence encoding the lead editing fusion protein, wherein the lead editing fusion protein comprises a CRISPR nuclease such as a CRISPR nickase and a PERV reverse transcriptase or a functional variant thereof; and / or

[0074] ii) at least one pegRNA and / or an expression construct containing a nucleotide sequence encoding the at least one pegRNA.

[0075] In some embodiments, the at least one pegRNA comprises, from 5' to 3' direction, a leader sequence, a scaffold sequence, a reverse transcription template (RTT) sequence, and a primer binding site (PBS) sequence.

[0076] On the other hand, the present invention also provides a lead editing fusion protein, which comprises a CRISPR nuclease such as a CRISPR nickase and a PERV reverse transcriptase or a functional variant thereof. The present invention also provides the use of the lead editing fusion protein for lead editing, particularly for use in lead editing in mammalian cells.

[0077] In some embodiments, the CRISPR nuclease, such as a CRISPR nickase, and the PERV reverse transcriptase or a functional variant thereof in the lead editing fusion protein are connected via a linker.

[0078] In some embodiments, the at least one pegRNA is capable of forming a complex with the CRISPR nuclease, such as a CRISPR nickase, the PERV reverse transcriptase, or a functional variant thereof and targeting the fusion protein to a target sequence in the genome, resulting in a nick within the target sequence.

[0079] In some embodiments, the at least one pegRNA is capable of forming a complex with the fusion protein and targeting the fusion protein to a target sequence in the genome, resulting in a nick within the target sequence.

[0080] As used herein, "lead editing system" refers to a combination of components required for reverse transcription-based genome editing of the genome in a cell. The individual components of the system, such as CRISPR nucleases such as CRISPR nickases, PERV reverse transcriptases or functional variants thereof, lead editing fusion proteins, pegRNA, etc., can exist independently of each other, or can exist in any combination as a composition.

[0081] As used herein, "target sequence" refers to a sequence of about 20 nucleotides in length characterized by a PAM (protospacer sequence adjacent motif) sequence on the 5' or 3' flank in the genome. Generally speaking, PAM is necessary for the complex formed by CRISPR nuclease or its variants and guide RNA to recognize the target sequence. For example, for Cas9 nuclease and its variants, its target sequence is adjacent to PAM at the 3' end, such as 5'-NGG-3'. Based on the presence of PAM, those skilled in the art can easily determine the target sequence that can be used for targeting in the genome. And depending on the position of PAM, the target sequence can be located on any chain of the genomic DNA molecule. For Cas9 or its derivatives such as Cas9 nickase, the target sequence is preferably 20 nucleotides.

[0082] The CRISPR nuclease of the present invention can be a CRISPR nuclease of different sources. Examples of CRISPR nucleases suitable for the present invention include, but are not limited to, Cas9, Cas12a (i.e., Cpf1), Cas12b (i.e., C2c1), Cas12c, Cas12d (i.e., CasY), Cas12e (i.e., CasX), Cas12f (i.e., Cas14), Cas12h, Cas12i, Cas12j (i.e., CasΦ), Cas12k, Cas12m, IsrB, IscB, and TnpB.

[0083] In some embodiments, the CRISPR nuclease also includes a nickase form thereof. A nickase form of a CRISPR nuclease may also be referred to herein as a CRISPR nickase, which forms a nick in only one strand of a double-stranded nucleic acid molecule, but does not completely cut off the double-stranded nucleic acid. In some embodiments, the CRISPR nickase is capable of forming a nick in a target sequence in genomic DNA. Those skilled in the art can obtain nickase forms of different CRISPR nucleases, for example, by mutating the nucleic acid cleavage domain of a CRISPR nuclease.

[0084] In some embodiments, the CRISPR nickase is a Cas9 nickase. However, the CRISPR nickase can also be derived from other CRISPR nucleases.

[0085] In some embodiments, the Cas9 nickase is derived from SpCas9 of Streptococcus pyogenes (S. pyogenes) and comprises at least an amino acid substitution H840A relative to wild-type SpCas9. In some embodiments, the Cas9 nickase comprises an amino acid sequence as shown in SEQ ID NO: 18. In some embodiments, the Cas9 nickase in the fusion protein is capable of forming a nick between the -3 nucleotide (the first nucleotide at the 5' end of the PAM sequence is +1) and the -4 nucleotide of the PAM of the target sequence.

[0086] In some embodiments, the Cas9 nickase is a Cas9 nickase variant that can recognize a changed PAM sequence. Many Cas9 nickase variants that can recognize a changed PAM sequence are known in the art. For example, the Cas9 nickase is a Cas9 variant that recognizes a PAM sequence 5'-NG-3'. These different variants can all be applied to the present invention.

[0087] The nick formed by the Cas9 nickase of the present invention can cause the target sequence to form a free single strand with a 3' end (3' free single strand) and a free single strand with a 5' end (5' free single strand).

[0088] In some embodiments, the PERV reverse transcriptase or a functional variant thereof in the fusion protein is the PERV reverse transcriptase or a functional variant thereof described above in the present invention.

[0089] In some embodiments, the PERV reverse transcriptase is from a type A, type B, or type C PERV, or from a recombinant of a different type of PERV, such as a type A / C PERV recombinant.

[0090] In some embodiments, the PERV is a PERV isolated from Bama Xiang pig. In some embodiments, the PERV is isolated from other breeds of pigs.

[0091] In some embodiments, the PERV reverse transcriptase or a functional variant thereof comprises an amino acid sequence of one of SEQ ID NOs: 1-5 or an amino acid sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or even at least 100% sequence identity to one of SEQ ID NOs: 1-5.

[0092] In some embodiments, the functional variant of the PERV reverse transcriptase lacks the RNase H domain. The RNase H domain of the PERV reverse transcriptase, for example, comprises an amino acid sequence corresponding to about position 514 to about position 616 of SEQ ID NO:5.

[0093] In some embodiments, the functional variant of the PERV reverse transcriptase comprises an amino acid substitution at one or more positions selected from position 199, 305, 312, 329, 330, 331, 332, or 602.

[0094] When referring to the amino acid position of PERV reverse transcriptase or a functional variant thereof herein, the amino acid position refers to SEQ ID NO:1.

[0095] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, and 312. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, and W312F.

[0096] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, and L602W.

[0097] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, 329, 330, 331, and 332. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, E329P, K330G, G331T, and E332C.

[0098] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, 329, 330, 331, 332, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, E329P, K330G, G331T, E332C, and L602W.

[0099] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 222, 305, 312, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, V222A, T305K, W312F, and L602W.

[0100] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 63, 199, 222, 305, 312, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions Y63R, D199N, V222A, T305K, W312F, and L602W.

[0101] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 222, 305, 312, 408, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, V222A, T305K, W312F, C408R, and L602W.

[0102] In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 63, 199, 222, 305, 312, 408, and 602. In some embodiments, the functional variant of the PERV reverse transcriptase comprises amino acid substitutions Y63R, D199N, V222A, T305K, W312F, C408R, and L602W.

[0103] In some specific embodiments, the functional variant of the PERV reverse transcriptase comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 6 (corresponding to AC-RT-M0Δ), SEQ ID NO: 7 (corresponding to AC-RT-M3Δ), SEQ ID NO: 8 (corresponding to AC-RT-M4Δ*), SEQ ID NO: 9 (corresponding to B-RT-M0Δ), SEQ ID NO: 10 (corresponding to B-RT-M3Δ), SEQ ID NO: 11 (corresponding to B-RT-M4Δ*), and SEQ ID NO: 12 (corresponding to bmx-A-RT-M4), SEQ ID NO: 13 (corresponding to bmx-B-RT-M4), SEQ ID NO: 14 (corresponding to bmx-C-RT-M4), SEQ ID NO: 15 (corresponding to bmx-A-RT-M3Δ), SEQ ID NO: 16 (corresponding to bmx-B-RT-M3Δ), SEQ ID NO: 17 (corresponding to bmx-C-RT-M3Δ), SEQ ID NO: 18 (corresponding to bmx-B-RT-M3Δ), SEQ ID NO: 19 (corresponding to bmx-C-RT-M3Δ), SEQ ID NO: 20 NO:40 (corresponding to bmx-C-RT-M5.1), SEQ ID NO:41 (corresponding to bmx-C-RT-M5.1+Y63R), SEQ ID NO:42 (corresponding to bmx-C-RT-M5.1+C408R), SEQ ID NO:43 (corresponding to bmx-C-RT-M7) and SEQ ID NO:44 (corresponding to bmx-C-RT-M7Δ).

[0104] In some embodiments, in the fusion protein, the reverse transcriptase or its functional variant is fused to a nucleocapsid protein (NC) directly or through a linker at the N-terminus or C-terminus. The nucleocapsid protein (NC) is, for example, from PERV. Preferably, the nucleocapsid protein and the reverse transcriptase are from the same type of PERV.

[0105] In some embodiments, the nucleocapsid protein comprises the amino acid sequence shown in SEQ ID NO: 19 or one of SEQ ID NOs: 36-39.

[0106] In some embodiments, the PERV reverse transcriptase or a functional variant thereof is fused to the nucleocapsid protein (NC) at the N-terminus, either directly or through a linker.

[0107] In some embodiments, the PERV reverse transcriptase or a functional variant thereof is fused to the nucleocapsid protein (NC) at the C-terminus directly or through a linker.

[0108] As used herein, a "joint" can be a non-functional amino acid sequence of 1-50 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 20-25, 25-50) or more amino acids in length, without a secondary or higher structure. For example, the joint can be a flexible joint, etc. For example, it can be an XTEN joint shown in SEQ ID NO: 20.

[0109] In some embodiments, the CRISPR nuclease, e.g., CRISPR nickase, in the fusion protein is located at the N-terminus of the reverse transcriptase and / or nucleocapsid protein. In some embodiments, the CRISPR nuclease, e.g., CRISPR nickase, in the fusion protein is located at the C-terminus of the reverse transcriptase and / or nucleocapsid protein.

[0110] In some embodiments of the present invention, the fusion protein of the present invention may further include a nuclear localization sequence (NLS). In general, one or more NLS in the fusion protein should have sufficient strength to drive the fusion protein in the nucleus of the cell to accumulate in an amount that can realize its base editing function. In general, the intensity of nuclear localization activity is determined by the number, position, one or more specific NLS used, or a combination of these factors of NLS in the fusion protein. However, depending on the DNA position to be edited, the lead editing fusion protein of the present invention may also include one or more other localization sequences, such as cytoplasmic localization sequences, chloroplast localization sequences, mitochondrial localization sequences, etc.

[0111] In some embodiments, the fusion protein may also include a selectable marker protein linked directly or via a self-cleavable peptide.

[0112] As used herein, "self-cleaving peptide" means a peptide that can achieve self-cleavage in a cell. For example, the self-cleaving peptide may include a protease recognition site, thereby being recognized and specifically cleaved by a protease in the cell.

[0113] Alternatively, the self-cleaving peptide can be a 2A polypeptide. 2A polypeptides are a class of short peptides from viruses, and their self-cleavage occurs during translation. When two different target proteins are expressed in the same reading frame using a 2A polypeptide, two target proteins are generated at almost a 1:1 ratio. Commonly used 2A polypeptides can be P2A from porcine techovirus-1, T2A from Thosea asigna virus, E2A from equine rhinitisA virus, and F2A from foot-and-mouth disease virus. Among them, P2A has the highest cleavage efficiency and is therefore preferred. A variety of functional variants of these 2A polypeptides are also known in the art, and these variants can also be used in the present invention.

[0114] An exemplary selectable marker protein is, for example, Puro-R protein. Puro-R protein can provide puromycin resistance to select positive cells. An exemplary Puro-R protein comprises the amino acid sequence shown in SEQ ID NO:35.

[0115] In some specific embodiments, the fusion protein comprises the amino acid sequence shown in one of SEQ ID NOs: 22-34 and 45-49.

[0116] The leader sequence (also called seed sequence or spacer sequence) in at least one pegRNA of the present invention is set to have sufficient sequence identity (preferably 100% identity) with the target sequence, so that it can bind to the complementary chain of the target sequence through base pairing to achieve sequence-specific targeting.

[0117] A variety of scaffold sequences suitable for gRNAs for genome editing based on CRISPR nucleases (e.g., Cas9) are known in the art, which can be used in the pegRNA of the present invention. In some specific embodiments, the scaffold sequence of the gRNA is shown in SEQ ID NO: 21.

[0118] In some embodiments, the primer binding sequence (PBS) is set to be complementary to at least a portion of the target sequence (preferably completely matched with at least a portion of the target sequence), preferably, the primer binding sequence is complementary to at least a portion of the 3' free single strand caused by the nick in the DNA chain where the target sequence is located (preferably completely matched with at least a portion of the 3' free single strand), in particular, complementary to the nucleotide sequence at the 3' end of the 3' free single strand (preferably completely matched). When the 3' free single strand of the chain binds to the primer binding sequence through base pairing, the 3' free single strand can serve as a primer, and reverse transcription is performed under the action of the reverse transcriptase or its functional variant in the fusion protein, and a DNA sequence corresponding to the reverse transcription (RT) template sequence is extended.

[0119] The primer binding sequence depends on the length of the free single strand formed by the CRISPR nickase used in the target sequence, however, it should have a minimum length to ensure specific binding. In some embodiments, the primer binding sequence length can be 4-20 nucleotides, for example, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides in length.

[0120] The RT template sequence described herein can be any sequence. Through the above-mentioned reverse transcription, its sequence information can be integrated into the DNA chain where the target sequence is located (i.e., the chain containing the target sequence PAM), and then through the DNA repair of the cell, a DNA double strand containing the RT template sequence information is formed. In some embodiments, the RT template sequence contains a desired modification. For example, the desired modification includes substitution, deletion and / or addition of one or more nucleotides. For example, the modification comprises one or more substitutions selected from the group consisting of C to T substitutions, C to G substitutions, C to A substitutions, G to T substitutions, G to C substitutions, G to A substitutions, A to T substitutions, A to G substitutions, A to C substitutions, T to C substitutions, T to G substitutions, T to A substitutions; and / or comprises a deletion of one or more nucleotides, such as 1 to about 100 or more, such as 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide deletions; and / or comprises an insertion of one or more nucleotides, such as 1 to about 100 or more, such as 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide insertions.

[0121] In some embodiments, the RT template sequence is set to correspond to the sequence downstream of the target sequence nick (e.g., complementary to at least a portion of the sequence downstream of the target sequence nick), and comprises a desired modification. The desired modification includes substitution, deletion and / or addition of one or more nucleotides. For example, the modification comprises one or more substitutions selected from the group consisting of C to T substitutions, C to G substitutions, C to A substitutions, G to T substitutions, G to C substitutions, G to A substitutions, A to T substitutions, A to G substitutions, A to C substitutions, T to C substitutions, T to G substitutions, T to A substitutions; and / or comprises a deletion of one or more nucleotides, such as 1 to about 100 or more, such as 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide deletions; and / or comprises an insertion of one or more nucleotides, such as 1 to about 100 or more, such as 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide insertions.

[0122] In some embodiments, the RT template sequence length can be about 1-300 or more nucleotides, such as 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100, about 125, about 150, about 175, about 200, about 225, about 250, about 275, about 300 nucleotides or more polynucleotides in length. Preferably, the RT template sequence length is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 nucleotides.

[0123] In some embodiments, the lead editing system further comprises a nicking gRNA (nicking gRNA, for producing additional nicks) and / or an expression construct containing a nucleotide sequence encoding the nicking gRNA, wherein the nicking gRNA comprises a leader sequence and a scaffold sequence. In some preferred embodiments, the nicking gRNA does not comprise a reverse transcription (RT) template sequence and a primer binding site (PBS) sequence.

[0124] The leader sequence (also called seed sequence or spacer sequence) in the nicking gRNA of the present invention is set to have sufficient sequence identity (preferably 100% identity) with the nicking target sequence in the genome, so that the fusion protein of the present invention can be targeted to the nicking target sequence and cause a nick in the nicking target sequence, and the nicking target sequence and the target sequence targeted by the pegRNA (pegRNA target sequence) are located on the opposite strand of the genomic DNA. In some embodiments, the nick formed by the nicking RNA and the nick formed by the pegRNA are about 1-about 300 or more nucleotides apart, for example, 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100, about 125, about 150, about 175, about 200, about 225, about 250, about 275, about 300 nucleotides or more nucleotides apart. In some embodiments, the nick formed by the nicking RNA is located upstream or downstream of the pegRNA (the upstream or downstream refers to the DNA chain where the pegRNA target sequence is located). In some embodiments, the leader sequence in the nicking gRNA has sufficient sequence identity (preferably 100% identity) with the relative chain (modified) of the pegRNA target sequence after the editing event occurs, so that the nicking gRNA only targets the nicking target sequence generated after the pegRNA-induced target sequence targeting and modification are completed. In some embodiments, the PAM of the nicking target sequence is located within the complementary sequence of the pegRNA target sequence.

[0125] In some embodiments, the lead editing system comprises at least one pair of pegRNA and / or an expression construct containing a nucleotide sequence encoding the at least one pair of pegRNA. In some embodiments, the two pegRNAs in the pegRNA pair are set to target different target sequences on the same strand of the genomic DNA. In some embodiments, the two pegRNAs in the pegRNA pair are set to target sequences on different strands of the genomic DNA. In some embodiments, the PAM of the target sequence of one pegRNA in the pegRNA pair is located in the sense strand, while the PAM of the other pegRNA is located in the antisense strand. In some embodiments, the induced cuts of the two pegRNAs are located on both sides of the site to be modified. In some embodiments, the cut induced by the pegRNA for the sense strand is located upstream (5' direction) of the site to be modified, and the cut induced by the pegRNA for the antisense strand is located downstream (3' direction) of the site to be modified. The upstream or downstream is relative to the sense strand. In some embodiments, the induced nicks of the two pegRNAs are about 1 to about 300 or more nucleotides apart, such as 1-15 nucleotides apart.

[0126] In some embodiments, the two pegRNAs in the pegRNA pair are configured to introduce the same desired modification. For example, one pegRNA is configured to introduce an A to G substitution in the sense strand, while the other pegRNA is configured to introduce a T to C substitution in the corresponding position of the antisense strand. For another example, one pegRNA is configured to introduce a deletion of two nucleotides in the sense strand, while the other pegRNA is configured to also introduce a deletion of two nucleotides in the corresponding position of the antisense strand. Other types of modifications can be deduced by analogy. The same desired modification can be achieved by designing a suitable RT template sequence to enable pegRNAs that target two different chains, respectively.

[0127] In some preferred embodiments, the pegRNA of the present invention is epegRNA. The construction of epegRNA can refer to James W. Nelson et al., Engineered pegRNAs improve prime editing efficiency. Nature Biotechnology volume 40, 402–410 (2022), which is incorporated herein by reference. In some embodiments, the epegRNA is an epegRNA modified with a 3'-tevopreQ1-8nt linker.

[0128] In some preferred embodiments, pegRNA of the present invention is Csy4-pegRNA.Csy4-pegRNA comprises Csy4 recognition sequence at the 3' end of pegRNA, such as Csy4 recognition sequence shown in SEQ ID NO:50.

[0129] In some preferred embodiments, pegRNA of the present invention is tCsy4-pegRNA.TCsy4-pegRNA comprises the Csy4 recognition sequence of the truncation at the 3' end of pegRNA, for example the Csy4 recognition sequence of the truncation shown in SEQ ID NO:51.

[0130] In order to achieve effective expression in different organisms, in some embodiments of the present invention, the nucleotide sequence encoding the fusion protein is codon-optimized for the species of the organism whose genome is to be modified.

[0131] Codon optimization refers to a method for modifying a nucleic acid sequence to enhance expression in a host cell of interest by replacing at least one codon (e.g., about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more codons) of a native sequence with a codon that is more frequently or most frequently used in the genes of a host cell. Different species show specific preferences for certain codons of specific amino acids. Codon preference (the difference in the use of codons between organisms) is often associated with the translation efficiency of messenger RNA (mRNA), and the translation efficiency is considered to depend on the properties of the codons translated and the availability of specific transfer RNA (tRNA) molecules. The advantage of the tRNA selected in the cell generally reflects the codons that are most frequently used for peptide synthesis. Therefore, genes can be customized to be based on codon optimization for optimal gene expression in a given organism. Codon utilization tables can be easily obtained, such as in the codon usage database ("Codon Usage Database") available on www.kazusa.orjp / codon / , and these tables can be adjusted and applied in different ways. See, Nakamura Y. et al., "Codon usage tabulated from the international DNA sequence databases: status for the year 2000. Nucl. Acids Res., 28:292 (2000).

[0132] On the other hand, the present invention also provides a truncated Csy4 recognition sequence element, whose nucleotide sequence is shown in SEQ ID NO:51. On the other hand, the present invention also provides a nucleic acid molecule such as an RNA molecule comprising the truncated Csy4 recognition sequence element. The RNA molecule is, for example, a gRNA, preferably a pegRNA. The gRNA and / or pegRNA are as defined above. On the other hand, the present invention also provides the use of the truncated Csy4 recognition sequence element in gene editing.

[0133] IV. Methods for Modifying Cell Genome Sequences

[0134] On the other hand, the present invention provides a method for modifying the genome sequence of a cell, comprising introducing the lead editing system of the present invention into at least one of the cells, thereby resulting in modification of the genome sequence of the at least one cell. The modification comprises substitution, deletion and / or addition of one or more nucleotides. For example, the modification comprises one or more substitutions selected from the group consisting of C to T substitutions, C to G substitutions, C to A substitutions, G to T substitutions, G to C substitutions, G to A substitutions, A to T substitutions, A to G substitutions, A to C substitutions, T to C substitutions, T to G substitutions, T to A substitutions; and / or comprises a deletion of one or more nucleotides, such as 1 to about 100 or more, such as 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide deletions; and / or comprises an insertion of one or more nucleotides, such as 1 to about 100 or more, such as 1 to about 100 or more, such as 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide insertions. The modification can be located in the target sequence of the pegRNA or near the target sequence, for example, downstream of the target sequence.

[0135] In some embodiments, the lead editing system is introduced into the cell in the presence of one or more small molecule compounds selected from RS-1, nocodazole (Noc) and trichostatin A (TSA) (preferably a combination of RS-1 and TSA or nocodazole, more preferably a combination of RS-1 and nocodazole).

[0136] In some embodiments, after the lead editing system is introduced into the cell, the cell is treated with one or more small molecule compounds selected from RS-1, nocodazole (Noc) and trichostatin A (TSA) (preferably a combination of RS-1 and TSA or nocodazole, more preferably a combination of RS-1 and nocodazole), for example, the cell is cultured in a culture medium containing the one or more small molecule cyclic compounds (preferably a combination of RS-1 and TSA or nocodazole, more preferably a combination of RS-1 and nocodazole).

[0137] The concentration of nocodazole can be about 50 ng / ml to about 500 ng / ml, such as about 100 ng / ml to about 300 ng / ml, preferably about 200 ng / mL. The concentration of RS-1 can be about 5 μM to about 50 μM, such as about 10 μM to about 30 μM, preferably about 20 μM. The concentration of trichostatin A can be about 1 nM to about 50 nM, such as about 5 nM to about 20 nM, preferably about 10 nM.

[0138] In another aspect, the present invention also provides a method for producing a genetically modified cell, comprising introducing the lead editing system of the present invention into the cell.

[0139] The genetic modification includes substitution, deletion and / or addition of one or more nucleotides. For example, the genetic modification comprises one or more substitutions selected from the group consisting of C to T substitutions, C to G substitutions, C to A substitutions, G to T substitutions, G to C substitutions, G to A substitutions, A to T substitutions, A to G substitutions, A to C substitutions, T to C substitutions, T to G substitutions, T to A substitutions; and / or comprises a deletion of one or more nucleotides, such as 1 to about 100 or more, such as 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide deletions; and / or comprises an insertion of one or more nucleotides, such as 1 to about 100 or more, such as 1 to about 100 or more, such as 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide insertions. The modification can be located in the target sequence of the pegRNA or near the target sequence, for example, downstream of the target sequence.

[0140] In some embodiments, the lead editing system is introduced into the cell in the presence of one or more small molecule compounds selected from RS-1, nocodazole (Noc) and trichostatin A (TSA), preferably RS-1 and nocodazole.

[0141] In some embodiments, after the lead editing system is introduced into the cell, the cell is treated with one or more small molecule compounds selected from RS-1, nocodazole (Noc) and trichostatin A (TSA) (preferably RS-1 and nocodazole), for example, the cell is cultured in a culture medium containing the one or more small molecule cyclic compounds (preferably RS-1 and nocodazole).

[0142] In another aspect, the present invention also provides a genetically modified organism comprising a genetically modified cell produced by the method of the present invention or a progeny cell thereof.

[0143] In the present invention, the modification can be located at any position of the genome, for example, in a functional gene such as a protein coding gene, or, for example, in a gene expression regulatory region such as a promoter region or an enhancer region, thereby achieving modification of the gene function or modification of gene expression. The modification in the cell genome sequence can be detected by T7EI, PCR / RE or sequencing methods.

[0144] In the method of the present invention, the prime editing system can be introduced into cells by various methods well known to those skilled in the art.

[0145] Methods that can be used to introduce the lead editing system of the present invention into cells include, but are not limited to, calcium phosphate transfection, protoplast fusion, electroporation, liposome transfection, microinjection, viral infection (such as baculovirus, vaccinia virus, adenovirus, adeno-associated virus, lentivirus and other viruses), gene gun method, PEG-mediated protoplast transformation, and soil Agrobacterium-mediated transformation.

[0146] Cells that can be gene-edited by the methods of the present invention can be derived from, for example, mammals such as humans, mice, rats, monkeys, dogs, pigs, sheep, cattle, cats; poultry such as chickens, ducks, geese; plants, including monocots and dicots, such as rice, corn, wheat, sorghum, barley, soybeans, peanuts, Arabidopsis, etc. In some preferred embodiments, the cells are derived from humans. In some preferred embodiments, the cells are derived from pigs.

[0147] In some embodiments, the methods of the invention are performed in vitro. For example, the cells are isolated cells, or cells in isolated tissues or organs.

[0148] In other embodiments, the method of the present invention can also be performed in vivo. For example, the cell is a cell in an organism, and the system of the present invention can be introduced into the cell in vivo by, for example, a virus or Agrobacterium-mediated method.

[0149] On the other hand, the present invention provides one or more small molecule compounds selected from RS-1, nocodazole (Noc) and trichostatin A (TSA) (preferably a combination of RS-1 and TSA or nocodazole, more preferably a combination of RS-1 and nocodazole) for use in lead editing, in particular for use in lead editing in mammalian cells.

[0150] 5. Therapeutic Application

[0151] The present invention also covers the use of the lead editing system of the present invention in disease treatment.

[0152] By modifying the disease-related genes through the lead editing system of the present invention, it is possible to achieve upregulation, downregulation, inactivation, activation or mutation correction of the disease-related genes, thereby achieving disease prevention and / or treatment. For example, the genome modification described in the present invention can be located in the protein coding region of the disease-related gene, or, for example, can be located in a gene expression regulatory region such as a promoter region or an enhancer region, so as to achieve functional modification of the disease-related gene or modification of the expression of the disease-related gene. Therefore, the modified disease-related genes described herein include modification of the disease-related gene itself (e.g., protein coding region), and also include modification of its expression regulatory region (e.g., promoter, enhancer, intron, etc.).

[0153] "Disease-related" gene refers to any gene that produces a transcription or translation product at an abnormal level or in an abnormal form in cells derived from tissues affected by the disease, compared to tissues or cells of non-disease controls. In the case where the altered expression is related to the appearance and / or progression of the disease, it can be a gene expressed at an abnormally high level; it can be a gene expressed at an abnormally low level. Disease-related genes also refer to genes with one or more mutations or genetic variations that are directly responsible or unbalanced with one or more genes responsible for the etiology of the disease. The mutation or genetic variation is, for example, a single nucleotide variation (SNV). The transcribed or translated product can be known or unknown, and can be at normal or abnormal levels.

[0154] Therefore, the present invention also provides a method for treating a disease in a subject in need, comprising delivering an effective amount of the lead editing system of the present invention to the subject to modify a gene associated with the disease. The present invention also provides the use of the lead editing system in the preparation of a pharmaceutical composition for treating a disease in a subject in need, wherein the lead editing system is used to modify a gene associated with the disease. The present invention also provides a pharmaceutical composition for treating a disease in a subject in need, comprising the lead editing system of the present invention, and an optional pharmaceutically acceptable carrier, wherein the lead editing system is used to modify a gene associated with the disease.

[0155] Preferably, the pharmaceutical composition of the present invention further comprises one or more small molecule compounds selected from RS-1, nocodazole and trichostatin A (TSA) (preferably a combination of RS-1 and TSA or nocodazole, more preferably a combination of RS-1 and nocodazole). In other preferred embodiments, the pharmaceutical composition of the present invention is used in combination with one or more small molecule compounds selected from RS-1, nocodazole and trichostatin A (TSA) (preferably a combination of RS-1 and TSA or nocodazole, more preferably a combination of RS-1 and nocodazole).

[0156] Preferably, the "subject" of the present invention is a mammal, such as a human, mouse, rat, monkey, dog, pig, sheep, cow or cat, preferably a human.

[0157] In some embodiments, the prime editing systems described herein are used to introduce point mutations into a nucleic acid.

[0158] In some embodiments, the lead editing system described in the present invention is used to cause the correction of genetic defects, such as in the correction of point mutations that cause loss of function in gene products. In some embodiments, genetic defects are associated with diseases or conditions (e.g., lysosomal storage diseases or metabolic diseases, such as type I diabetes). In some embodiments, the methods provided herein can be used to introduce inactivating point mutations into genes or alleles encoding gene products associated with diseases or conditions.

[0159] In some embodiments, the purpose of the scheme described in the present invention is to treat a disease associated with or caused by a point mutation, which can be corrected by the lead editing system provided herein. In some embodiments, the disease is a proliferative disease. In some embodiments, the disease is a genetic disease. In some embodiments, the disease is a neoplastic disease. In some embodiments, the disease is a metabolic disease. In some embodiments, the disease is a lysosomal storage disease.

[0160] In some embodiments, the invention describes a method for treating mitochondrial diseases or disorders. As used herein, "mitochondrial diseases" refer to diseases caused by abnormal mitochondria, such as mitochondrial gene mutations, enzyme pathways, etc. Examples of diseases include, but are not limited to: neurological diseases, loss of motor control, muscle weakness and pain, gastrointestinal diseases and dysphagia, poor growth, heart disease, liver disease, diabetes, respiratory complications, epilepsy, vision / hearing problems, lactic acidosis, developmental delays, and susceptibility to infection.

[0161] Examples of diseases described in the present invention include, but are not limited to, genetic diseases, circulatory system diseases, muscle diseases, brain, central nervous and immune system diseases, Alzheimer's disease, secretase disorders, amyotrophic lateral sclerosis (ALS), autism, trinucleotide repeat expansion disorders, hearing diseases, gene-targeted therapy of non-dividing cells (neurons, muscles), liver and kidney diseases, epithelial cell and lung diseases, cancer, Usher syndrome or retinitis pigmentosa-39, cystic fibrosis, HIV and AIDS, beta thalassemia, sickle cell disease, herpes simplex virus, autism, drug addiction, age-related macular degeneration, schizophrenia. Other diseases treated by correcting point mutations or introducing inactivating mutations into disease-related genes are known to those skilled in the art, and therefore the present disclosure is not limited in this regard. In addition to the diseases exemplarily described in the present invention, other related diseases can also be treated with the strategies and lead editing systems provided by the present invention, and the application is obvious to those skilled in the art.

[0162] The administration of the lead editing system or pharmaceutical composition of the present invention can be adjusted for the weight and species of the patient or subject. The frequency of administration is within the range permitted by medicine or veterinary medicine. It depends on conventional factors including the age, sex, general health, other conditions of the patient or subject, and the specific condition or symptom being addressed.

[0163] 6. Test kit

[0164] The present invention also includes a kit for the method of the present invention, the kit comprising the components of the lead editing system of the present invention. The kit may also include a reagent for introducing the lead editing system into an organism or a cell of an organism. The kit generally includes a label indicating the intended use and / or method of use of the contents of the kit. The term label includes any written or recorded material provided on or with the kit or otherwise provided with the kit. Example

[0165] Example 1: Acquisition and analysis of PERV-RT sequences.

[0166] Acquisition of PERV sequence: PERV-A / C (accession number: AY953542) and PERV-B (accession number: AY099324) sequences were obtained through the NCBI database. The position and sequence of NC, RT and RNase H in the PERV sequence were analyzed using the conserved domain database to obtain PERV-AC-NC, PERV-B-NC, PERV-AC-RT (ΔRNase H) and PERV-B-RT (ΔRNase H).

[0167] Sequence analysis: The DNA sequences of MMLV-RT (ΔRNase H), PERV-AC-RT (ΔRNase H) and PERV-B-RT (ΔRNase H) were converted into protein sequences, and the differences among MMLV-RT (ΔRNase H), PERV-AC-RT (ΔRNase H) and PERV-B-RT (ΔRNase H) were compared using MegAlign (V7.1.0) software. Figure 1 ). The results showed that PERV-AC-RT and PERV-B-RT were highly similar, with only 11 amino acid differences; while the similarity between PERV-RT and MMLV-RT was only 70%, with 153 and 150 amino acid differences between PERV-AC and PERV-B and MMLV-RT, respectively. It is worth noting that among the four mutation sites of MMLV-RT in PE2, three have homology with PERV-RT ( Figure 1 , red box), there is one site with no homology, and the four consecutive bases at this site are not homologous to PERV-RT ( Figure 1 , black box).

[0168] Example 2: Construction of enhanced PERV-PE editor (epPE)

[0169] 2.1 Upgrade PE2 editor and get PE2c-Puro

[0170] In order to enhance the editing efficiency of lead editing in mammalian cells, the present invention first upgrades the PE2 editor. First, the PE2 plasmid (number: #132775) was purchased from the Addgene plasmid sharing platform in the United States, and the online codon optimization tool (https: / / www.genscript.com.cn / codon-opt.html) was used to optimize the MMLV-RT in PE2 and the pig genome for specific codons to obtain the MMLV-RT (condon opt) sequence. Nanjing GenScript Biotechnology Co., Ltd. was commissioned to synthesize the sequence and replace it with the MMLV-RT sequence of the PE2 vector to obtain the PE2c vector. In addition, the 2A-Puro sequence was synthesized and inserted into the C-terminus of the RT structure of the PE2c vector. The resulting vector was named PE2c-Puro ( Figure 2 ).

[0171] 2.2 Construction of epPE editor.

[0172] 2.2.1 Construction of epPE-AC / B-m3-Puro

[0173] Using an online codon optimization tool (https: / / www.genscript.com.cn / codon-opt.html), specific codon optimization was performed on the PERV-AC-RT (ΔRNase H) and PERV-B-RT (ΔRNase H) sequences according to the porcine genome, and corresponding mutations were performed on the three mutation sites (M3) homologous to MMLV-RT in PE2 (D200N, T306K, and W313F in MMLV-RT, corresponding to D199N, T305K, and W312F in PERV-RT), to obtain PERV-AC-RT-M3Δ and PERV-B-RT-M3Δ sequences, respectively. Nanjing GenScript Biotechnology Co., Ltd. was commissioned to synthesize the PERV-AC-RT-M3Δ and PERV-B-RT-M3Δ sequences and replace them with the MMLV-RT in PE2c-Puro, to obtain epPE-AC-M3Δ-Puro and epPE-B-M3Δ-Puro ( Figure 2 ).

[0174] 2.2.2 Construction of epPE-AC / B-m4-Puro

[0175] Nanjing GenScript Biotech Co., Ltd. was commissioned to mutate the amino acids 329-332 of RT in epPE-AC-M3Δ-Puro and epPE-B-M3Δ-Puro from EKGE to PGTL (DNA sequence mutated from GAGAAGGGTGAA / GAGAAGGGAGAG to CCAGGCACCCTG), thus obtaining epPE-AC-M4Δ*-Puro and epPE-B-M4Δ*-Puro ( Figure 2 ).

[0176] Example 3: Testing the efficiency of different epPEs in immortalized BFP fluorescent reporter porcine fetal fibroblast (PFF) cells

[0177] 3.1 Construction of pegRNA and ngRNA

[0178] The pegRNA vector backbone pegRNA-GG (No. 132777) and ngRNA vector backbone (No. 107721) were purchased from the Addgene plasmid sharing platform in the United States, and the vector plasmid DNA was extracted using the Takata MidiBest Kit (Takara, China).

[0179] Vector digestion: 1×CutSmart buffer (Neb, USA), 1 μL of BsaI endonuclease (Neb, USA) and 2 μg of pegRNA-GG or ngRNA empty plasmid DNA were placed in a PCR instrument for digestion at 37°C for 2 hours and inactivated at 80°C for 15 minutes. The digestion products were separated by 1.5% agarose gel and purified using Axypre DNA GelExtraction Kit (Axygen, USA).

[0180] The forward and reverse primers of pegRNA-gRNA, pegRNA 3'-extension, sgRNA scaffold, and ngRNA were annealed into double strands: 100 μM / L of forward primer (F) and reverse primer (R), double distilled water, and 1×T4 Ligation Buffer (Neb, USA) were respectively contained in a 25 μL reaction system; the EP tube containing the reaction system was sealed and placed in a beaker filled with boiling water and slowly cooled at room temperature.

[0181] pegRNA connection: The connection system is shown in Table 1. After the system is prepared, it is placed at room temperature for 10 minutes, then transferred to a PCR instrument at 16°C for 5 minutes, 37°C for 15 minutes (8 cycles), and finally inactivated at 80°C for 15 minutes.

[0182] Table 1 pegRNA ligation system

[0183]

[0184] Ligation of ngRNA: 1 μL of annealed ngRNA was ligated in a 10 μL system at room temperature for 15 minutes under the action of Quick Ligase (Neb, USA), and then stored in a -20°C refrigerator.

[0185] Preparation of high-purity plasmid. Take 5 μL of the ligated pegRNA / ngRNA and transform it into 5α competent cells (Qingke Biotechnology, China), the transformed cells were spread on solid LB plates (each liter of LB solid medium contains 10g peptone, 5g yeast extract, 10g NaCl, 15g agar powder, and 30mg ampicillin) and cultured overnight in a 37°C incubator. Six clones were selected for each pegRNA / ngRNA and expanded in 1mL liquid LB medium. 500μL was sent to Qingke Biotechnology Co., Ltd. for Sanger sequencing (sequencing primer is U6-F: atggactatcatatgcttaccgta), and the correctly connected clones were selected and added to 200mL liquid LB medium and cultured overnight at 37°C in a shaking incubator. High-purity, endotoxin-free plasmid DNA was extracted using the Takata MidiBestKit (Takara, China) kit.

[0186] 3.2 Cell culture, electroporation and puromycin selection.

[0187] 3.2.1 Cell culture

[0188] The immortalized BFP fluorescent reporter PFF cell line was cultured in high-glucose DMEM (Gibco, USA) containing 12% fetal bovine serum ((v / v), Excell, China) and 1% penicillin-streptomycin ((v / v), BI, China). This cell line was constructed by our laboratory. First, the SV40 large T antigen was site-specifically knocked into the H11 safe harbor site of Bamaxiang primary PFFs using CRISPRCas9 technology, and then the BFP vector was site-specifically integrated into the Rosa26 safe harbor site of immortalized PFF using CRISPRCas9 technology. Finally, the BFP fluorescent reporter PFF cell line was obtained by continuous passage.

[0189] 3.2.2 Electroporation

[0190] When the cell confluence reached 85-90%, the cells were digested with 0.125% trypsin (Gibco, USA) and counted using a hemocytometer. Approximately 4 × 10 5 The cells were placed in a 15 mL centrifuge tube and centrifuged at 200 × g for 5 minutes. After the supernatant was discarded, 20 μL Entranster-E electroporation solution (Ingen, China), 1 μg PE editor, 0.5 μg pegRNA, and 0.5 μg ngRNA were added. After mixing, the cell suspension was transferred to a 16-well electroporation strip (Lonza, Germany) and placed in the electroporation strip holder of the 4D-NucleofectorTM electroporator. PFF cells were electroporated twice continuously using the CA137 program, and the electroporated cells were cultured in a 6-well cell culture dish. The culture medium was replaced 7 hours after electroporation to remove dead cells caused by electroporation.

[0191] 3.2.2 Puromycin drug screening

[0192] 48 hours after electroporation, 2 μg / mL puromycin (Sigma, Japan) was added for selection for 1 day, and then the culture medium was replaced and cultured for another 3 days.

[0193] 3.3 Editing efficiency detection

[0194] After digesting the cells with 0.125% trypsin (Gibco, USA), the cells were collected into a 1.5 mL EP tube and centrifuged at 200 × g for 5 minutes. After the supernatant was discarded, 50 μL of 1 × PBS buffer was added to resuspend the cells. The cells were detected using a flow cytometer (BD, USA). The wild-type fluorescent reporter cells were used as the background, and GFP-positive cells were circled using the FITC+PE dual channel. The GFP ratio was the editing efficiency.

[0195] Flow cytometry showed that the efficiency of the epPE editors from the four PERV-RT sources was significantly higher (p < 0.01) than that of the PE2c-Puro editor from mouse RT, and that the efficiency of epPE-AC-M3Δ-Puro was higher than that of epPE-B-M3Δ-Puro (p = 0.007), and that of epPE-AC-M4Δ*-Puro was higher than that of epPE-B-M4Δ*-Puro (p = 0.012). Figure 3 ) Example 4: Testing the efficiency of type AC and type B PERV-RT epPE in primary PFF cells

[0196] 4.1 Acquisition of primary PFF cells

[0197] The sows at 31 days of gestation were euthanized and then dissected. After the entire uterus was removed, the fetuses were removed one by one along with the fetal membranes and transferred to a DMEM solution containing 5% (v / v) penicillin and streptomycin (v / v; Gibco: 15140-122) and stored in a refrigerator at 4°C. In the clean bench, the separated fetuses were transferred one by one to a sterile 10 cm culture dish, and the head, internal organs, limbs and tail of the fetus were removed with sterile forceps and scissors; the remaining part of the fetus was cleaned with a PBS solution containing 5% (v / v) penicillin and streptomycin (Gibco: 15140-122) and then chopped into about 1 mm within 10-15 minutes. 3, add 5ml collagenase working solution to the shredded tissue; cut the tip of the 1ml sterile pipette with scissors, transfer the shredded tissue pieces to a 15ml sterile centrifuge tube, seal it with a sealing film and incubate it in a 37℃ shaker for 2 hours. After that, centrifuge the centrifuge tube at 1000rpm for 5 minutes, remove the upper layer of collagenase working solution, transfer the incubated tissue pieces evenly into two T75 culture dishes and place them in a sterile incubator at 37℃ and 5% CO2 for culture. Continue to culture until the next morning (Note: about 20 hours after the start of cell culture, if the cell culture medium turns yellow, replace it with a new culture medium), observe the cell adhesion and separation from the cell tissue under a microscope, and when the cell proliferation and growth confluence reaches more than 85%, the construction of the primary porcine PFF cell line is completed, and it can be frozen or subcultured.

[0198] 4.2 Primary PFF cell culture, electroporation and puromycin selection

[0199] The cells were cultured in high-glucose DMEM (Gibco, USA) supplemented with 12% (v / v) fetal bovine serum (Excell, China) and 1% (v / v) penicillin-streptomycin (BI, China) at 37°C in a 5% carbon dioxide incubator. When the cell confluence reached 85-90%, 0.125% trypsin (Gibco, USA) was used to digest the cells and counted using a blood cell counting plate. For each electroporation reaction, 4×10^5 cells were taken in a 15mL centrifuge tube and centrifuged at 200×g for 5 minutes. After aspirating the supernatant, 20μLEntranster-E electroporation solution (Ingen, China), 1μg PE editor, 0.5μg pegRNA, and 0.5μg ngRNA were added. After mixing, the cell suspension was transferred to a 16-well electroporation strip (Lonza, Germany) and placed in the electroporation strip holder of the 4D-NucleofectorTM electroporator. The CA-137 program was used for two consecutive electroporations. The electroporated cells were placed in a 6-well cell culture dish for culture. The culture medium was replaced 7 hours after electroporation to remove dead cells caused by electroporation. 2μg / mL puromycin (Sigma, Japan) was added 48 hours after electroporation for 1 day of screening, and then the culture medium was replaced for 3 days.

[0200] 4.3 Editing efficiency detection

[0201] 4.3.1 Cell DNA acquisition

[0202] The cells were digested with 0.125% trypsin and collected into a 200 μL EP tube, centrifuged at 750×g for 5 minutes, and the supernatant was removed using a vacuum aspirator. 12 μL of cell lysis buffer (0.45% NP40 lysis buffer (Gibco, USA), 6% proteinase K (Sigma, Japan) was added to resuspend the cells and placed in a PCR instrument. The reaction program was: 56°C for 1.5 hours, 85°C for 15 minutes.

[0203] 4.3.2 Target site amplification.

[0204] Two rounds of PCR amplification were performed on the target sites using the corresponding primers, in which the first round of PCR amplified the target sites, and the second round of PCR used labeled primers to label the samples. Both rounds of PCR were amplified using PrimeSTAR Max DNA Polymerase (Takara, Japan). Each reaction contained 8 μL PrimeSTAR Max DNA Polymerase buffer, 1 μL each of forward and reverse primers, 1 μL DNA template, and 5 μL ultrapure water. PCR reaction conditions: 94°C for 5 minutes; (94°C for 30 seconds, 68°C (0.5°C lowered for each cycle) for 30 seconds, 72°C for 1 minute) for 26 cycles; (94°C for 30 seconds, 55°C for 30 seconds, 72°C for 1 minute) for 14 cycles; 72°C for 5 minutes.

[0205] 4.3.3 Sample mixing and gel cutting and purification. The amplified products with different labels were mixed in the manner of 5 μL per sample and 8-12 samples as a group. After adding the loading buffer to the mixed sample, 2% agarose gel was used for electrophoresis separation at 180V for 20 minutes, and then the target fragment tape was cut on the UV gel cutting table. Axypre DNA Gel Extraction Kit (Axygen, USA) was used to purify and recover according to the method instructed in the manual, and finally ultrapure water was used to dissolve the DNA.

[0206] 4.3.4 High-throughput sequencing. Take 2 μg of the purified PCR product and submit it to Beijing Novogene Technology Co., Ltd. for library construction and sequencing. First use Ultra TM The DNA Library Prep Kit for Illumina was used to add an A-tail to the DNA and connect it to the Illumina sequencing adapter. The DNA was then purified using the AMPure XP system, and the DNA was quantified and diluted using Qubit 3.0. The insert fragments of the library were detected using Agilent 2100, and for libraries with insert fragments that met the expected size, the effective concentration was accurately quantified using the Q-PCR method. Afterwards, the PE150 platform of the Illumina high-throughput sequencer NovaSeq 6000 was used for double-end sequencing.

[0207] 4.3.5 Editing efficiency analysis

[0208] First, Fastp (V0.19.7) software was used to filter the sequences with base quality values ​​Qphred≤5 and N content in the read exceeding 10% of the number of bases in the read to obtain Clean Data. Fastq-multx (V1.31) software was used to split the mixed sample data, and R1.fastq and R2.fastq were obtained for each sample. CRISPResso2 (V2.0.43) software was used to analyze the editing efficiency. Ref_seq, pegRNA_spacer_seq, pegRNA_extension_pegRNA_scaffold_seq and nicking_guide_seq were provided for each sample, and the other parameters used the default values. Among them, ref_seq is the reference sequence amplified by PCR, and the pegRNA_extension_pegRNA_scaffold_seq sequence is the complete sgRNA scaffold sequence. For the final result, Prime-edited UNMODIFILED is considered as precise editing, and other editing types are considered as unwanted byproducts.

[0209] The results showed that among the six editing sites tested in primary PFF, the average editing efficiency of the epPE editor derived from PERV-RT was higher than that of the PE2c-Puro editor derived from mouse RT, and the average efficiency of epPE-AC-M3Δ-Puro was higher than that of epPE-B-M3Δ-Puro ( Figure 4 ).

[0210] Example 5: Testing the efficiency of epPE in other cells

[0211] 5.1 Cell culture

[0212] Canine fetal fibroblasts (DFF) were isolated from 30-day-old female fetuses, and the specific establishment method was consistent with that of PFF; sheep fetal fibroblasts (SFF) were donated by the laboratory of Wei Hongjiang of Yunnan Agricultural University, and the cells were isolated from small-tailed Han sheep fetuses; 293T cells were purchased from the cell bank of the Type Culture Collection Committee of the Chinese Academy of Sciences. All three cells were cultured in a high-glucose DMEM (Gibco, USA) culture medium containing 12% (v / v) fetal bovine serum (Excell, China) and 1% (v / v) penicillin-streptomycin (BI, China), at 37°C and a 5% carbon dioxide incubator.

[0213] 5.2 Cell transfection

[0214] DFF and SFF: The method is similar to the transfection method of PFF. The difference is that for DFF and SFF, the EN-150 program is used for electroporation, and then the CA-113 program is used for electroporation again.

[0215] 293T cells: 1-2 days before cell transfection, cells were seeded into 24-well culture dishes. When the cell confluence reached 50-60%, transfection was performed using Lipofectamine 3000 reagent (Invitrogen, USA). Each transfection reaction included 1 μg PE editor, 0.5 μg pegRNA, 0.5 μg ngRNA and 1 μL Lipofectamine 3000 reagent.

[0216] 5.3 Puromycin Drug Screening

[0217] SFF and DFF cells: 48 hours after electroporation, 3 μg / mL puromycin (Sigma, Japan) was added for selection for 2 days, and then the culture medium was replaced and cultured for another 2 days.

[0218] 293T cells: 48 hours after transfection, 3 μg / mL puromycin (Sigma, Japan) was added for selection for 3 days, and then the culture medium was replaced and cultured for another 2 days.

[0219] 5.4 Editing efficiency detection

[0220] The method is consistent with the editing efficiency of PFF.

[0221] After analysis, such as Figure 5 As shown, the efficiency of epPE editor in other mammals such as SFF, DFF and 293T is higher than that of PE2c-Puro vector of mouse MMLV-RT.

[0222] Example 6: Application of RT of PERV isolated from Bama Xiang pig in lead editing

[0223] The inventors also isolated three types of PERV-RT (bmx-PERV-A-RT-M0, bmx-PERV-B-RT-M0 and bmx-PERV-C-RT-M0) from Bama Xiang pig DNA by PCR amplification, and replaced the MMLV-RT in the PE2c-Puro vector respectively to obtain pPE editors of PERV-RT A, B and C, respectively, and constructed PE editors carrying different mutation sites for bmx-PERV-RT; M0 represents the wild type and does not contain mutations; M4 represents 4 mutations (D199N, T305K, W312F and L602W), such as Figure 6 The PERV-RT and corresponding lead editors involved in the isolation of Bama Xiang pig are preceded by "bmx-" to distinguish them from the PERV-RT and corresponding lead editors from NCBI.

[0224] The editing activities of different editors in different cell lines were tested as described above.

[0225] Figure 7 It was shown that in the BFP reporter gene cell line, the pPE editor containing Bama Xiang pig type C PERV reverse transcriptase had a higher editing activity, and after introducing mutations, the three PERV-RTs could obtain higher editing activity.

[0226] Figure 8 The editing efficiency of the Bama Xiang pig PERV reverse transcriptase pPE editor containing 4 point mutations in PFF is shown, and bmx-pPE-C-M4-puro shows an overall higher efficiency.

[0227] Fig. 9 The editing efficiency of the Bama Xiang pig PERV reverse transcriptase pPE editor containing 4 point mutations in HEK293T, canine fetal fibroblasts, and sheep fetal fibroblasts is shown. bmx-pPE-C-M4-puro showed higher efficiency at most sites.

[0228] Fig.10 The editing efficiency of the Bama Xiang pig PERV reverse transcriptase epPE editor containing 4 point mutations in PFF is shown. Compared with type A and type B bmx-epPE, type C bmx-epPE editor shows an overall higher efficiency and is significantly higher than bmx-pPE.

[0229] Fig.11 The figure shows the editing efficiency of the C-type bmx-epPE editor (bmx-epPE-C-M3Δ-Puro) in HEK293T, canine fetal fibroblasts, and sheep fetal fibroblasts. The overall editing efficiency of bmx-epPE-C-M3Δ-Puro in the three cell lines was significantly higher than that of bmx-pPE-C-M4-Puro.

[0230] Example 7: The PERV-RT lead editing system of the Ma Xiang pig carrying 7 point mutations has higher efficiency

[0231] Based on the fact that type C bmx-PERV-RT has a higher editing efficiency in the lead editing system, the inventors screened a large number of mutation sites for type C bmx-PERV-RT in 293T cells.

[0232] 7.1 Selection of mutation sites

[0233] 7.1.1 Mutation sites that have been reported in the MMLV-RT prime editing system and have homology with PERV-RT.

[0234] According to the reports of Anzalone et al. Nature (2019) and Ni et al. Genome Biology (2023), sites that are effective in the MMLV-RT prime editing system and have homology with PERV-RT were selected, and six potential favorable sites, D199N, T305K, W312F, E329P, L602W and V222A, were obtained.

[0235] 7.1.2 Use molecular docking to obtain potential favorable mutation sites.

[0236] Mutating the polar negatively charged amino acids (D, E) and polar uncharged amino acids (S, T, C, N, Q, Y, G) in RT that bind to DNA or RNA into polar positively charged amino acids (R, K) may enhance the interaction between RT and DNA / RNA and thus improve the efficiency of prime editing. To this end, the present invention uses Phyre2 software to obtain the predicted protein structure of the bmx-PERV-C-RT-M5.1 variant, and downloads the PDB file of the MMLV-RT-DNA-RNA complex from the PDB database: 4KHQ, uses PyMOL software to compare the bmx-PERV-C-RT-M5.1 variant with 4KHQ, finds out the amino acids that interact with bmx-PERV-C-RT-M5.1 and DNA / RNA, and selects all polar negatively charged amino acids and polar uncharged amino acids to mutate into R, and obtains a total of 11 mutation sites: Y43R, Y108R, Q112R, D113R, E116R, D149R, D152R, G190R, N118R, N130R, G269R, T305R, and Y324R.

[0237] 7.1.3 Obtaining Potential Favorable Sites Based on Literature Reports

[0238] 7.1.3.1 Select mutation sites that have been reported to improve the reverse transcription performance of MMLV-RT but have not been verified in the PE system and have homology with PERV-RT. A total of 7 potential mutation sites were obtained: S86R, Q112R, Q189F, Q220R, T286A, E332Q, and I434R.

[0239] 7.1.3.2 Doman et al. Cell (2023) used a phage-assisted evolution system to obtain a large number of mutation sites, but the efficiency of these mutation sites has not been verified in the PE system. The present invention screened out 9 high-frequency mutation sites that are homologous to PERV-RT: T127N, P131S, P195S, K232N, E338N, C408R, D423V, M456I, and T457I.

[0240] 7.2 293T cell fluorescent reporter gene co-transfection experiment

[0241] 17-24 hours before cell transfection, add 1×10 5 Cells were seeded into 24-well culture dishes, and when the cell confluence reached 50-80%, H4000 reagent (Ingen, China) was used for transfection. Each transfection reaction included 200ng PE editor, 100ng pegRNA, 100ng ngRNA, 10ng fluorescent reporter gene vector and 0.5μL H4000 reagent. Cells were collected 48 hours after transfection and detected using a flow cytometer (BD, USA). Wild-type fluorescent reporter cells were used as the background, and FITC+PE dual channels were used to circle GFP-positive cells. The GFP ratio was the editing efficiency.

[0242] 7.3 Editing experiments at endogenous editing sites in 293T cells

[0243] 17-24 hours before cell transfection, add 1×10 5 Cells were seeded into 24-well culture dishes, and when the cell confluence reached 50-80%, H4000 reagent (Ingen, China) was used for transfection. Each transfection reaction included 400ng PE editor, 200ng pegRNA, 200ng ngRNA, and 1μL H4000 reagent. The culture medium was replaced 24 hours after transfection, and the cells were collected about 72 hours after transfection. The editing efficiency was detected by referring to the method in 4.3.

[0244] Fig.12 The data show the efficiency of six mutation sites and their combinations that have been reported in the MMLV-RT pilot editing system and are homologous to PERV-RT in the C-type bmx-PERV-RT in the 293T cell fluorescent reporter gene co-transfection experiment. The data indicate that the PERV-RT variant (named M5.1) carrying five amino acid mutations (D199N, T305K, W312F, L602W, V222A) exhibited the best overall efficiency among the three editing forms.

[0245] Fig.13 The efficiency of the M5.1-based pvPE editor in further superimposing new potentially favorable mutation sites in 293T cells is shown. Fig.13 A shows the efficiency of a total of 27 new potential favorable sites reported in the literature using molecular docking in a 293T cell fluorescent reporter gene co-transfection experiment, of which 8 sites significantly reduced PE editing efficiency. Fig.13 B shows the efficiency of the remaining 19 mutation sites at the endogenous sites of 293T cells, among which Y63R and C408R showed different degrees of improvement in editing efficiency.

[0246] Fig.14 The editing efficiencies of M5.1, M5.1+Y63R, M5.1+C408R and their combination M5.1+Y63R+C408R (M7) at endogenous sites in 293T cells were shown. The results showed that M7 exhibited overlapping editing efficiencies at multiple sites, and its efficiency at all sites was significantly better than that of M5.1.

[0247] Fig.15 The editing efficiency of the M7-based epPE editor in 293T cells is shown, and the efficiency of bmx-epPE-C-M7Δ superimposed with 7 point mutations is further improved compared to bmx-pPE-C-M7.

[0248] Fig.16 The results show that the efficiency of bmx-epPE-C-M7Δ is higher than that of PEmax, PE6c, PE6d and other editors with the best efficiency in 293T cells.

[0249] Example 8, tCsy4-pegRNA has higher editing efficiency

[0250] The 3' end of conventional pegRNA is a naked RNA, which is easily degraded in cells, thus affecting the efficiency of pegRNA. In addition, since PBS is usually 10-16nt at the 3' end of pegRNA and is complementary to part of the spacer at the 5' end of pegRNA, their annealing is expected to cause pegRNA circularization, which may hinder editing. It is reported that by adding the Csy4 recognition sequence (hairpin structure) to the end of pegRNA, the efficiency of PE in HKE293T, HeLa and Neuro-2a cells is significantly improved. The inventors also designed a truncated Csy4 (tCsy4, SEQ ID NO: 51). The editing efficiency of tCsy4-pegRNA was compared with that of Csy4-pegRNA and conventional pegRNA ( Fig.17 A). The results showed that the editing efficiency of Csy4-pegRNA (5 out of 7 sites) and tCsy4-pegRNA (6 out of 7 sites) was significantly higher than that of conventional pegRNA, and the editing efficiency of tCsy4-pegRNA was similar to or higher than that of Csy4-pegRNA ( Fig.17 B, C). In addition, the efficiency of tCsy4-pegRNA in HEK293T, DFF, and SFF was verified, and the data showed that tCsy4-pegRNA could further improve the PE efficiency in the three cell lines ( Fig.17 D).

[0251] Example 9: Small molecules can significantly improve the efficiency of lead editing in mammalian cells

[0252] It is known that some small molecule compounds can significantly improve the efficiency of CRISPR / Cas9 genome editing. Based on this, it is inferred that some small molecules may also improve the editing efficiency of PE. First, nine small molecules that have been proven to be effective in the CRISPR / Cas9 system were tested in the fluorescent reporter gene PFF cell line: 10μM Scr7, 2μM Nu7441, 25μM L189, 40μM L755507, 5μM Yu238259, 0.1μM Brefeldin A, 10nM TSA, 20μM RS-1, 200ng / mL Nocodazole, 25μM L189. After transfection, the corresponding concentrations of small molecules or small molecule combinations were added to the culture medium to treat the cells.

[0253] The data showed that L755507, BrefeldinA, TSA, Rs-1 and Nocodazole significantly (P<0.05 or P<0.01) improved PE efficiency, among which TSA, Rs-1 and Nocodazole were more effective, increasing the editing efficiency by 34.4%, 32.7% and 66.9% ( Fig.18 A). The combination of Rs-1+TSA or Rs-1+Nocodazole significantly increased (P<0.01) the editing efficiency compared to the use of a single molecule. The Rs-1+Nocodazole group had the highest editing efficiency, increasing the efficiency by 106.0% compared to the DMSO group ( Fig.18 B). Then, the effects of Rs-1, Nocodazole, TSA, and the combination of Rs-1+TSA and Rs-1+Nocodazole were verified in primary PFFs. The data showed that in primary PFFs using Rs-1, TSA, and Nocodazole, the overall editing efficiency for these six sites increased by 20.8%, 14.3%, and 36.4%, respectively. The Rs-1+Nocodazole combination increased the editing efficiency by 60.54%, while the Rs-1+TSA combination did not show an additive effect ( Fig.18 C). In addition, the efficiency of the Rs-1+Nocodazole combination was verified in HEK293T, DFF, and SFF. The data showed that the Rs-1+Nocodazole combination could further improve the PE efficiency in all three cell lines ( Fig.18 D) Information on small molecule compounds involved in the present invention

[0254] RS-1:

[0255] Selleck part number: S8234,

[0256] MedChemExpress(MCE)Product No.:HY-19793

[0257] Chemical formula: C 20 H 16 Br2N2O3S

[0258] structure:

[0259]

[0260] Nocodazole

[0261] Selleck Part Number: S2775

[0262] MedChemExpress(MCE)Product No.:HY-13520

[0263] Chemical formula: C 14 H 11 N3O3S

[0264] structure:

[0265]

[0266] Trichostatin A (TSA)

[0267] Selleck Part Number: S1045

[0268] MedChemExpress(MCE)Product No.:HY-15144

[0269] Chemical formula: C 17 H 22 N2O3

[0270] structure:

[0271]

[0272] Sequence information related to the present invention

[0273] SEQ ID NO:1PERV-AC-RT-M0

[0274] TLQLDDEYRLYSPQVKPDQDIQSWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSREAREGIWPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLSALPPERNWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSPTIFDEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKKTVVQIPAPTTAKQVREFLGTAGFCRLWIPGFATLAAPLYPLTKEKGEFSWAPEHQKTFDAIKKALLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIEETGVRKDLTDIPL TGEVLTWFTDGSSYVVEG KRMAGAAVVDGTHTIWASSLPEGTSAQKAELMALTQALRLAEGKSINIYTDSRYAFATAHVHGAIYKQRGLLTSAGR EIKNKEEILSLLEALHLPKRLAIIHCPGHQKAKDLISRGNQMADRVAKQAAQAVNLLPIIETPKAPEPRRQ

[0275] Note: The underlined part is the RNase H domain

[0276] SEQ ID NO:2 PERV - B - RT - M0

[0277] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSKEAQEGIRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSPTIFDEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRDGQRWLTEARKKTVVQIPAPTTAKQVREFLGTAGFCRLWIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIEETGVRKDLTDIPL TGEVLTWFTDGSSYVVEG KRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQALRLAEGKSINIYTDSRYAFATAHVHGAIYKQRGLLTSAGR EIKNKEEILSLLEALHLPKRLAIIHCPGHQKAKDPISRGNQMADRVAKQAAQGVNLLPMIETPKAPEPGRQ

[0278] Note: The underlined part is the RNase H domain

[0279] SEQ ID NO:3bmx - PERV - A - RT - M0

[0280] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSKEAREGIRSHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFDEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLMEARKKTVVQIPAPTTAKQVREFLGTAGFCRLWIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEEADEPVTHDCHQLLIEETGVRKDLTDIPL TGEVLTWFTDRSSYVVEG KRMAGAAVVDGTHTIWASSLPEGTSAQKAELMALTQALRLAEGKSINIYTDSRYAFATAHVHRAIYKQRGLLTSAGR EIKNKEEILSLLEALHLPKRLAIIHCPGHQKAKDPISRGNQMADRVTKQAAQGVNLLPIIETPKAPEP

[0281] Note: The underlined part is the RNase H domain

[0282] SEQ ID NO:4bmx - PERV - B - RT - M0

[0283] TLQLDDEYRLYSPQVKPDQDIQSWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSREAREGIWPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLSALPPEQNWYTVLDLKDAFFCLRLHPTSQPLFAFKWRDPGTGRTGQLTWTRLPQGFKNSPTIFDEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKKTVVQIPAPTTAKQVREFLGTAGFCRLWIPGFATLAAPLYLLTKEKGEFSWAPEHQKAFDAIKKSLLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNACMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIEETGVRKDLTDIPL TGEVLTWFTDGSSYVVEG KRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQALRLAEGKSINIYTDSRYAFATAHVHGAIYKQRGLLTSAGR EIKNKEEILSLLEALHLPKRLAIIHCPGHQKAKDLISRGNQMADRVAKQAAQAVNLLPIIETPKAPEP

[0284] Note: The underlined part is the RNase H domain

[0285] SEQ ID NO:5bmx - PERV - C - RT - M0

[0286] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQYPLSKEAREGIRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFDEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKRTVVQIPAPTTAKQVREFLGTAGFCRLWIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIEETGVRKDLTDIPL TGEVLTWFTDGSSYVVEG KRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQALRLAEGKSINIYTDSRYAFATAHVHGAIYKQRGLLTSAGR EIKNKEEILSLLEALHLPKRLAIIHCPGHQKAKDPISRGNQMADRVAKQAAQGVNLLPIIETPKAPEP

[0287] Note: The underlined part is the RNase H domain

[0288] SEQ ID NO:6 AC-RT-M0Δ

[0289] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSKEAQEGIRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSPTIFDEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRDGQRWLTEARKKTVVQIPAPTTAKQVREFLGTAGFCRLWIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIEETGVRKDLTDIPL

[0290] SEQ ID NO:7 AC-RT-M3Δ

[0291] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSKEAQEGIRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRDGQRWLTEARKKTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIEETGVRKDLTDIPL

[0292] SEQ ID NO:8 AC-RT-M4Δ*

[0293] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSKEAQEGIRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRDGQRWLTEARKKTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKPGTLFSWAPEHQKAFDAIKKALLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIEETGVRKDLTDIPL

[0294] SEQ ID NO:9 B-RT-M0Δ

[0295] TLQLDDEYRLYSPQVKPDQDIQSWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSREAREGIWPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLSALPPERNWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSPTIFDEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKKTVVQIPAPTTAKQVREFLGTAGFCRLWIPGFATLAAPLYPLTKEKGEFSWAPEHQKTFDAIKKALLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIEETGVRKDLTDIPL

[0296] SEQ ID NO:10 B-RT-M3Δ

[0297] TLQLDDEYRLYSPQVKPDQDIQSWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSREAREGIWPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLSALPPERNWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKKTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKTFDAIKKALLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIEETGVRKDLTDIPL

[0298] SEQ ID NO:11 B-RT-M4Δ*

[0299] TLQLDDEYRLYSPQVKPDQDIQSWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSREAREGIWPHVQRLIQQGILVVPQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLSALPPERNWYTVLDLKDAFFCLRLHPTSQPLFAEWRDPGTGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAK KAQICRREVTYLGYSLRGGQRWLTEARKKTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKPGTLFSWAPEHQKTFDAIKKALLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAANLPATLLPEETDEPVTHCHQLLIEETGVRKDLTDIPL

[0300] SEQ ID NO:12 bmx-A-RT-M4

[0301] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSKEAREGIRSHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLMEARKKTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEEADEPVTHDCHQLLIEETGVRKDLTDIPL TGEVLTWFTDRSSYVVEG KRMAGAAVVDGTHTIWASSLPEGTSAQKAELMALTQALLRLAEGKSINIYTDSRYAFATAHVHRAIYKRGWLTSAGR EIKNKEEILSLLEALHLPKRLAIIHCPGHQKAKDPISRGNQMADRVTKQAAQGVNLLPIIETPKAPEP

[0302] Note: The underlined part is the RNase H domain

[0303] SEQ ID NO:13 bmx-B-RT-M4

[0304] TLQLDDEYRLYSPQVKPDQDIQSWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSREAREGIWPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLSALPPEQNWYTVLDLKDAFFCLRLHPTSQPLFAFKWRDPGTGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKKTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYLLTKEKGEFSWAPEHQKAFDAIKKSLLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNACMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIEETGVRKDLTDIPL TGEVLTWFTDGSSYVVEG KRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQALLRLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGR EIKNKEEILSLLEALHLPKRLAIIHCPGHQKAKDLISRGNQMADRVAKQAAQAVNLLPIIETPKAPEP

[0305] Note: The underlined part is the RNase H domain

[0306] SEQ ID NO:14 bmx-C-RT-M4

[0307] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQYPLSKEAREGIRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKRTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIEETGVRKDLTDIPL TGEVLTWFTDGSSYVVEG KRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQALLRLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGR EIKNKEEILSLLEALHLPKRLAIIHCPGHQKAKDPISRGNQMADRVAKQAAQGVNLLPIIETPKAPEP

[0308] Note: The underlined part is the RNase H domain

[0309] SEQ ID NO:15 bmx-A-RT-M3ΔTLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSKEAREGIRSHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLMEARKKTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEEADEPVTHDCHQLLIEETGVRKDLTDIPL

[0310] SEQ ID NO:16 bmx-B-RT-M3Δ

[0311] TLQLDDEYRLYSPQVKPDQDIQSWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSREAREGIWPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLSALPPEQNWYTVLDLKDAFFCLRLHPTSQPLFAFKWRDPGTGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKKTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYLLTKEKGEFSWAPEHQKAFDAIKKSLLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNACMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIEETGVRKDLTDIPL

[0312] SEQ ID NO:17 bmx-C-RT-M3Δ

[0313] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQYPLSKEAREGIRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRSWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHPQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKRTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPALALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTLGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLLIEETGVRKDLTDIPL

[0314] SEQ ID NO:18 SpCas9(H840A)

[0315]

[0316] SEQ ID NO:19 PERV-AC-NC

[0317] DFRKIRSGPRQSGNLGNRTPLDKDQCAYCKEKGHWARNCPKKGNKGLKVLALEEDK

[0318] SEQ ID NO:20 XTEN

[0319] SGGSSGGSSGSETPGTSESATPESSGGSSGGSS

[0320] SEQ ID NO:21 gRNA scaffold sequence

[0321] GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGC

[0322] SEQ ID NO:22 epPE-AC-M3Δ

[0323] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0324] DSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0325] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0326] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0327] SKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0328] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0329] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEITITPWNFE

[0330] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0331] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVL

[0332] TLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0333] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0334] ARENQTTQKGQKNSRERMKRIEGIGELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0335] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0336] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIVERKVITLSKLVSDFRKDFQFYKVR

[0337] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0338] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0339] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0340] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0341] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0342] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSSD

[0343] FRKIRSGPRQSGNLGNRTPLDKDQCAYCKEKGHWARNCPKKGNKGLKVLALEEDKSGSETPGTSESATPES

[0344] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSKEAQE

[0345] GIRPHVQRLIQQGILVVPQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQR

[0346] SWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQH

[0347] PQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRDGQRWLTEARK

[0348] KTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPA

[0349] LALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLT

[0350] LGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQL

[0351] LIEETGVRKDLTDIPLSGGSKRTADGSEFEPKKKRKV

[0352] SEQ ID NO:23 epPE-AC-M4Δ*

[0353] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0354] DSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0355] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0356] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0357] SKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0358] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0359] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE

[0360] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0361] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDELEDIVL

[0362] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0363] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0364] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0365] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0366] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0367] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0368] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0369] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0370] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0371] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0372] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSSD

[0373] FRKIRSGPRQSGNLGNRTPLDKDQCAYCKEKGHWARNCPKKGNKGLKVLALEEDKSGSETPGTSESATPES

[0374] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSKEAQE

[0375] GIRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQR

[0376] SWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGTGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQH

[0377] PQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRDGQRWLTEARK

[0378] KTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKPGTLFSWAPEHQKAFDAIKKALLSAPA

[0379] LALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLT

[0380] LGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQL

[0381] LIEETGVRKDLTDIPLSGGSKRTADGSEFEPKKKRKV

[0382] SEQ ID NO:24 epPE-B-M3Δ

[0383] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0384] DSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0385] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0386] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0387] SKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0388] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0389] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE

[0390] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0391] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDELEDIVL

[0392] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0393] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0394] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0395] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0396] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0397] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0398] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0399] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0400] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0401] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0402] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSSD

[0403] FRKIRSGPRQSGNLGNRTPLDKDQCAYCKEKGHWARNCPKKGNKGPKVLALEEDKSGSETPGTSESATPES

[0404] TLQLDDEYRLYSPQVKPDQDIQSWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSREARE

[0405] GIWPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLSALPPER

[0406] NWYTVLDLKDAFFCLRLHPTSQPLFAWERWDPGTGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQH

[0407] PQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARK

[0408] KTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKTFDAIKKALLSAPA

[0409] LALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLT

[0410] LGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQL

[0411] LIEETGVRKDLTDIPLSGGSKRTADGSEFEPKKKRKV

[0412] SEQ ID NO:25 epPE-B-M4Δ*

[0413] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0414] DSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0415] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0416] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0417] SKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0418] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0419] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE

[0420] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0421] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDELEDIVL

[0422] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0423] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0424] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0425] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0426] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0427] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0428] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0429] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0430] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0431] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0432] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSSD

[0433] FRKIRSGPRQSGNLGNRTPLDKDQCAYCKEKGHWARNCPKKGNKGPKVLALEEDKSGSETPGTSESATPES

[0434] TLQLDDEYRLYSPQVKPDQDIQSWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSREARE

[0435] GIWPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLSALPPER

[0436] NWYTVLDLKDAFFCLRLHPTSQPLFAWERWDPGTGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQH

[0437] PQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARK

[0438] KTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKPGTLFSWAPEHQKTFDAIKKALLSAPA

[0439] LALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLT

[0440] LGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAANLPATLLPEETDEPVTHDCHQL

[0441] LIEETGVRKDLTDIPLSGGSKRTADGSEFEPKKKRKV

[0442] SEQ ID NO:26 bmx-pPE-A-M0

[0443] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0444] DSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0445] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAMHIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0446] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0447] SKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0448] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0449] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEITITPWNFE

[0450] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0451] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVL

[0452] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0453] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0454] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0455] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0456] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0457] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0458] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0459] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0460] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0461] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0462] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSST

[0463] LQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSKEAREG

[0464] IRSHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRS

[0465] WYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFDEALHRDLANFRIQHP

[0466] QVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLMEARKK

[0467] TVVQIPAPTTAKQVREFLGTAGFCRLWIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPAL

[0468] ALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTL

[0469] GQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEEADEPVTHDCHQLL

[0470] IEETGVRKDLTDIPLTGEVLTWFTDRSSYVVEGKRMAGAAVVDGTHTIWASSLPEGTSAQKAELMALTQAL

[0471] RLAEGKSINIYTDSRYAFATAHVHRAIYKQRGLLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQKA

[0472] KDPISRGNQMADRVTKQAAQGVNLLPI IETPKAPPSGGSKRTADGSEFEPKKKRKV

[0473] SEQ ID NO:27 bmx-pPE-B-M0

[0474] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0475] DSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0476] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAMHIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0477] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0478] SKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0479] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0480] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEITITPWNFE

[0481] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0482] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVL

[0483] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0484] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0485] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0486] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0487] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0488] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0489] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0490] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0491] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0492] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0493] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSST

[0494] LQLDDEYRLYSPQVKPDQDIQSWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSREAREG

[0495] IWPHVQRLIQQGILVVPQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLSALPPEQN

[0496] WYTVLDLKDAFFCLRLHPTSQPLFAKWRDPGTGRTGQLTWTRLPQGFKNSPTIFDEALHRDLANFRIQHP

[0497] QVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKK

[0498] TVVQIPAPTTAKQVREFLGTAGFCRLWIPGFATLAAPLYLLTKEKGEFSWAPEHQKAFDAIKKSLLSAPAL

[0499] ALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTL

[0500] GQNITVIAPHALENIVRQPPDRWMTNACMTHYQSLLLTERTVTFAPPAANLPATLLPEETDEPVTHDCHQLL

[0501] IEETGVRKDLTDIPLTGEVLTWFTDGSSSYVVEGKRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQAL

[0502] RLAEGKSINIYTDSRYAFATAHVHGAIYKQRGLLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQKA

[0503] KDLISRGNQMADRVAKQAAQAVNLLPI IETPKAPPSGGSKRTADGSEFEPKKKRKV

[0504] SEQ ID NO:28 bmx-pPE-C-M0

[0505] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0506] DSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0507] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAMHIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0508] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0509] SKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0510] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0511] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEITITPWNFE

[0512] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0513] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVL

[0514] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0515] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0516] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0517] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0518] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0519] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0520] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0521] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0522] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0523] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0524] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSST

[0525] LQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQYPLSKEAREG

[0526] IRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRS

[0527] WYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFDEALHRDLANFRIQHP

[0528] QVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKR

[0529] TVVQIPAPTTAKQVREFLGTAGFCRLWIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPAL

[0530] ALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTL

[0531] GQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLL

[0532] IEETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQAL

[0533] RLAEGKSINIYTDSRYAFATAHVHGAIYKQRGLLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQKA

[0534] KDPISRGNQMADRVAKQAAQGVNLLPI IETKPAPEPSGGSKRTADGSEFEPKKKRKV

[0535] SEQ ID NO:29 bmx-pPE-A-M4

[0536] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0537] DSGETAEATRLKRTARRRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0538] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAMHIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0539] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0540] SKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0541] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0542] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE

[0543] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0544] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDELEDIVL

[0545] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0546] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0547] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0548] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0549] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0550] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0551] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0552] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0553] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0554] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0555] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSST

[0556] LQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSKEAREG

[0557] IRSHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRS

[0558] WYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHP

[0559] QVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLMEARKK

[0560] TVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPAL

[0561] ALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTL

[0562] GQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEEADEPVTHDCHQLL

[0563] IEETGVRKDLTDIPLTGEVLTWFTDRSSYVVEGKRMAGAAVVDGTHTIWASSLPEGTSAQKAELMALTQAL

[0564] RLAEGKSINIYTDSRYAFATAHVHRAIYKQRGWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQKA

[0565] KDPISRGNQMADRVTKQAAQGVNLLPI IETKPAPEPSGGSKRTADGSEFEPKKKRKV

[0566] SEQ ID NO:30 bmx-pPE-B-M4

[0567] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0568] DSGETAEATRLKRTARRRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0569] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAMHIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0570] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0571] SKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0572] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0573] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE

[0574] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0575] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDELEDIVL

[0576] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0577] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0578] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0579] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0580] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0581] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0582] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0583] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0584] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0585] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0586] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSST

[0587] LQLDDEYRLYSPQVKPDQDIQSWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSREAREG

[0588] IWPHVQRLIQQGILVVPQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLSALPPEQN

[0589] WYTVLDLKDAFFCLRLHPTSQPLFAKWRDPGTGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHP

[0590] QVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKK

[0591] TVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYLLTKEKGEFSWAPEHQKAFDAIKKSLLSAPAL

[0592] ALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTL

[0593] GQNITVIAPHALENIVRQPPDRWMTNACMTHYQSLLLTERTVTFAPPAANLPATLLPEETDEPVTHDCHQLL

[0594] IEETGVRKDLTDIPLTGEVLTWFTDGSSSYVVEGKRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQAL

[0595] RLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQKA

[0596] KDLISRGNQMADRVAKQAAQAVNLLPI IETKPAPEPSGGSKRTADGSEFEPKKKRKV

[0597] SEQ ID NO:31 bmx-pPE-C-M4

[0598] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0599] DSGETAEATRLKRTARRRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0600] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAMHIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0601] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0602] SKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0603] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0604] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE

[0605] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0606] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDELEDIVL

[0607] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0608] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0609] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0610] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0611] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0612] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0613] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0614] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0615] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0616] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0617] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSST

[0618] LQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQYPLSKEAREG

[0619] IRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRS

[0620] WYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHP

[0621] QVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKR

[0622] TVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPAL

[0623] ALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTL

[0624] GQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLL

[0625] IEETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQAL

[0626] RLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQKA

[0627] KDPISRGNQMADRVAKQAAQGVNLLPI IETPKAPEPSGGSKRTADGSEFEPKKKRKV

[0628] SEQ ID NO:32 bmx-epPE-A-M3Δ

[0629] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0630] DSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0631] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0632] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0633] SKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0634] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0635] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE

[0636] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0637] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVL

[0638] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0639] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0640] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0641] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0642] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0643] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0644] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0645] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0646] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0647] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0648] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSSD

[0649] FRKIRSGPRQSGNLGNRTPLDKDQCAYCKEKGHWARDCPKKGNKGLKVLALEEDKSGSETPGTSESATPES

[0650] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSKEARE

[0651] GIRSHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQR

[0652] SWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQH

[0653] PQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLMEARK

[0654] KTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPA

[0655] LALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLT

[0656] LGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEEADEPVTHDCHQL

[0657] LIEETGVRKDLTDIPLTGEVLTWFTDRSSYVVEGKRMAGAAVVDGTHTIWASSLPEGTSAQKAELMALTQA

[0658] LRLAEGKSINIYTDSRYAFATAHVHRAIYKQRGWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQK

[0659] AKDPISRGNQMADRVTKQAAQGVNLLPIIETPKAPEPSGGSKRTADGSEFEPKKKRKV

[0660] SEQ ID NO:33 bmx-epPE-B-M3Δ

[0661] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0662] DSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0663] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0664] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0665] SKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0666] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0667] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE

[0668] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0669] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDELEDIVL

[0670] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0671] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0672] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0673] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0674] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0675] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0676] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0677] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0678] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0679] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0680] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSSD

[0681] FRKIRSGPRQSGNLGNRTPLDKDQCAYCKKKGHWARNCPKKGNKGPKVLALEEDKSGSETPGTSESATPES

[0682] TLQLDDEYRLYSPQVKPDQDIQSWLEQFPQAWAETAGMGLAKQVPPQVIQLKASATPVSVRQYPLSREARE

[0683] GIWPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLSALPPEQ

[0684] NWYTVLDLKDAFFCLRLHPTSQPLFAKWRDPGTGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQH

[0685] PQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARK

[0686] KTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYLLTKEKGEFSWAPEHQKAFDAIKKSLLSAPA

[0687] LALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLT

[0688] LGQNITVIAPHALENIVRQPPDRWMTNACMTHYQSLLLTERVTFAPPAANLPATLLPEETDEPVTHDCHQL

[0689] LIEETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQA

[0690] LRLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQK

[0691] AKDLISRGNQMADRVAKQAAQAVNLLPIIETPKAPEPSGGSKRTADGSEFEPKKKRKV

[0692] SEQ ID NO:34bmx-epPE-C-M3Δ

[0693] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0694] DSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0695] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0696] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0697] SKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0698] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0699] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE

[0700] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0701] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDELEDIVL

[0702] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0703] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0704] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0705] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0706] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0707] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0708] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0709] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0710] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0711] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0712] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSSD

[0713] FRKIRSGPRQLGNLGNRTPLDKDQCAYCKEKGHWARDCPKKGNKGLKVLALEEDKSGSETPGTSESATPES

[0714] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQYPLSKEARE

[0715] GIRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQR

[0716] SWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQH

[0717] PQVTLLQYVDDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARK

[0718] RTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPA

[0719] LALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLT

[0720] LGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQL

[0721] LIEETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQA

[0722] LRLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQK

[0723] AKDPISRGNQMADRVAKQAAQGVNLLPIIETPKAPEPSGGSKRTADGSEFEPKKKRKV

[0724] SEQ ID NO:35 Amino acid sequence of Puro R

[0725] MTEYKPTVRLATRDDVPRAVRTLAAAFADYPATRHTVDPDRHIERVTELQELFLTRVGLDIGKVWVADDGA

[0726] AVAVWTTPESVEAGAVFAEIGPRMAELSGSRLAAQQQMEGLLAPHRPKEPAWFLATVGVSPDHQGKGLGSA

[0727] VVLPGVEAAERAGVPAFLETSAPRNLPFYERLGFTVTADVEVPEGPRTWCMTRKPGA

[0728] SEQ ID NO:36 PERV-B-NC

[0729] DFRKIRSGPRQSGNLGNRTPLDKDQCAYCKEKGHWARNCPKKGNKGPKVLALEEDK

[0730] SEQ ID NO:37 bmx-PERV-A-NC

[0731] DFRKIRSGPRQSGNLGNRTPLDKDQCAYCKEKGHWARDCPKKGNKGLKVLALEEDK

[0732] SEQ ID NO:38 bmx-PERV-B-NC

[0733] DFRKIRSGPRQSGNLGNRTPLDKDQCAYCKKKGHWARNCPKKGNKGPKVLALEEDK

[0734] SEQ ID NO:39 bmx-PERV-C-NC

[0735] DFRKIRSGPRQLGNLGNRTPLDKDQCAYCKEKGHWARDCPKKGNKGLKVLALEEDK

[0736] SEQ ID NO:40 bmx-C-RT-M5.1

[0737] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQYPLSKEARE

[0738] GIRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQR

[0739] SWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQH

[0740] PQVTLLQYADDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARK

[0741] RTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPA

[0742] LALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLT

[0743] LGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQL

[0744] LIEETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQA

[0745] LRLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQK

[0746] AKDPISRGNQMADRVAKQAA

[0747] SEQ ID NO:41 bmx-C-RT-M5.1+Y63R

[0748] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQRPLSKEARE

[0749] GIRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQR

[0750] SWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQH

[0751] PQVTLLQYADDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARK

[0752] RTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPA

[0753] LALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLT

[0754] LGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQL

[0755] LIEETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQA

[0756] LRLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQK

[0757] AKDPISRGNQMADRVAKQAA

[0758] SEQ ID NO:42 bmx-C-RT-M5.1+C408R

[0759] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQYPLSKEARE

[0760] GIRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQR

[0761] SWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQH

[0762] PQVTLLQYADDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARK

[0763] RTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPA

[0764] LALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVRLKAIAAVAILVKDADKLT

[0765] LGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQL

[0766] LIEETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQA

[0767] LRLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQK

[0768] AKDPISRGNQMADRVAKQAA

[0769] SEQ ID NO:43 bmx-C-RT-M7

[0770] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQRPLSKEARE

[0771] GIRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQR

[0772] SWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQH

[0773] PQVTLLQYADDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARK

[0774] RTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPA

[0775] LALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVRLKAIAAVAILVKDADKLT

[0776] LGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQL

[0777] LIEETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQA

[0778] LRLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQK

[0779] AKDPISRGNQMADRVAKQAA

[0780] SEQ ID NO:44 bmx-C-RT-M7Δ

[0781] TLQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQRPLSKEARE

[0782] GIRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQR

[0783] SWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQH

[0784] PQVTLLQYADDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARK

[0785] RTVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPA

[0786] LALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVRLKAIAAVAILVKDADKLT

[0787] LGQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQL

[0788] LIEETGVRKDLTDIPL

[0789] SEQ ID NO:45 bmx-pPE-C-M5.1

[0790] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0791] DSGETAEATRLKRTARRRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0792] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0793] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0794] SKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0795] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0796] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE

[0797] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0798] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVL

[0799] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0800] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0801] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0802] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0803] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0804] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0805] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0806] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0807] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0808] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0809] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSST

[0810] LQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQYPLSKEAREG

[0811] IRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRS

[0812] WYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHP

[0813] QVTLLQYADDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKR

[0814] TVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPAL

[0815] ALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTL

[0816] GQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLL

[0817] IEETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQAL

[0818] RLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQKA

[0819] KDPISRGNQMADRVAKQAA

[0820] SEQ ID NO:46 bmx-pPE-C-M5.1+Y63R

[0821] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0822] DSGETAEATRLKRTARRRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0823] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0824] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0825] SKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0826] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0827] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE

[0828] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0829] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVL

[0830] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0831] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0832] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0833] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0834] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0835] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0836] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0837] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0838] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0839] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0840] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSST

[0841] LQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQRPLSKEAREG

[0842] IRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRS

[0843] WYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHP

[0844] QVTLLQYADDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKR

[0845] TVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPAL

[0846] ALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVCLKAIAAVAILVKDADKLTL

[0847] GQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLL

[0848] IEETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQAL

[0849] RLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQKA

[0850] KDPISRGNQMADRVAKQAA

[0851] SEQ ID NO:47 bmx-pPE-C-M5.1+C408R

[0852] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0853] DSGETAEATRLKRTARRRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0854] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0855] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0856] SKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0857] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0858] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE

[0859] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0860] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVL

[0861] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0862] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0863] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0864] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0865] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0866] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0867] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0868] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0869] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0870] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0871] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSST

[0872] LQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQYPLSKEAREG

[0873] IRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRS

[0874] WYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHP

[0875] QVTLLQYADDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKR

[0876] TVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPAL

[0877] ALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVRLKAIAAVAILVKDADKLTL

[0878] GQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLL

[0879] IEETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQAL

[0880] RLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQKA

[0881] KDPISRGNQMADRVAKQAA

[0882] SEQ ID NO:48 bmx-pPE-C-M7

[0883] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0884] DSGETAEATRLKRTARRRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0885] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0886] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0887] SKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0888] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0889] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE

[0890] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0891] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVL

[0892] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0893] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0894] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0895] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0896] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0897] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0898] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0899] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0900] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0901] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0902] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSST

[0903] LQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQRPLSKEAREG

[0904] IRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRS

[0905] WYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHP

[0906] QVTLLQYADDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKR

[0907] TVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPAL

[0908] ALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVRLKAIAAVAILVKDADKLTL

[0909] GQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLL

[0910] IEETGVRKDLTDIPLTGEVLTWFTDGSSYVVEGKRMAGAAVVDGTRTIWASSLPEGTSAQKAELMALTQAL

[0911] RLAEGKSINIYTDSRYAFATAHVHGAIYKQRGWLTSAGREIKNKEEILSLLEALHLPKRLAIIHCPGHQKA

[0912] KDPISRGNQMADRVAKQAA

[0913] SEQ ID NO:49 bmx-epPE-C-M7Δ

[0914] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLF

[0915] DSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD

[0916] EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQL

[0917] FEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQL

[0918] SKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKA

[0919] LVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

[0920] SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE

[0921] EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD

[0922] LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVL

[0923] TLTLFEDREMIEEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN

[0924] FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEM

[0925] ARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS

[0926] DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER

[0927] GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR

[0928] EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFK

[0929] TEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK

[0930] LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE

[0931] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE

[0932] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI

[0933] DRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSST

[0934] LQLDDEYRLYSPLVKPDQNIQFWLEQFPQAWAETAGVGLAKQVPPQVIQLKASATPVSVRQRPLSKEAREG

[0935] IRPHVQRLIQQGILVPVQSPWNTPLLPVRKPGTNDYRPVQDLREVNKRVQDIHPTVPNPYNLLCALPPQRS

[0936] WYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPGAGRTGQLTWTRLPQGFKNSPTIFNEALHRDLANFRIQHP

[0937] QVTLLQYADDLLLAGATKQDCLEGTKALLLELSDLGYRASAKKAQICRREVTYLGYSLRGGQRWLTEARKR

[0938] TVVQIPAPTTAKQVREFLGKAGFCRLFIPGFATLAAPLYPLTKEKGEFSWAPEHQKAFDAIKKALLSAPAL

[0939] ALPDVTKPFTLYVDERKGVARGVLTQTLGPWRRPVAYLSKKLDPVASGWPVRLKAIAAVAILVKDADKLTL

[0940] GQNITVIAPHALENIVRQPPDRWMTNARMTHYQSLLLTERVTFAPPAALNPATLLPEETDEPVTHDCHQLL

[0941] IEETGVRKDLTDIPL

[0942] SEQ ID NO:50 Csy4

[0943] GTTCACTGCCGTATAGGCAG

[0944] SEQ ID NO:51 tCsy4

[0945] CTGCCGTATAGGCAG

Claims

1. A lead editing system for targeted modification of an organism's genomic DNA sequence, comprising: i) (a) a CRISPR nuclease such as a CRISPR nickase and / or an expression construct comprising a nucleotide sequence encoding said CRISPR nuclease such as a CRISPR nickase, and a PERV reverse transcriptase or a functional variant thereof and / or an expression construct comprising a nucleotide sequence encoding said PERV reverse transcriptase or a functional variant thereof; or (b) a lead editing fusion protein and / or an expression construct containing a nucleotide sequence encoding the lead editing fusion protein, wherein the lead editing fusion protein comprises a CRISPR nuclease such as a CRISPR nickase and a PERV reverse transcriptase or a functional variant thereof; and / or ii) at least one pegRNA and / or an expression construct containing a nucleotide sequence encoding said at least one pegRNA, The at least one pegRNA comprises a leader sequence, a scaffold sequence, a reverse transcription template (RTT) sequence and a primer binding site (PBS) sequence from 5' to 3' direction.

2. The prime editing system of claim 1, wherein the PERV reverse transcriptase is from type A, type B or type C PERV, or from a recombinant of a different type of PERV, such as a type A / C PERV recombinant.

3. The lead editing system of claim 1 or 2, wherein the PERV is a PERV isolated from Bama Xiang pig.

4. The lead editing system of any one of claims 1-3, wherein the PERV reverse transcriptase or a functional variant thereof comprises an amino acid sequence of one of SEQ ID NOs: 1-5 or an amino acid sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with one of SEQ ID NOs: 1-5.

5. The prime editing system of any one of claims 1 to 4, wherein the functional variant of the PERV reverse transcriptase lacks the RNase H domain.

6. The lead editing system of any one of claims 1-5, wherein the functional variant of the PERV reverse transcriptase comprises an amino acid substitution at one or more positions selected from position 63, 199, 222, 305, 312, 329, 330, 331, 332, 408 or 602.

7. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, and 312.

8. The prime editing system of claim 7, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, and W312F.

9. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, and 602.

10. The prime editing system of claim 9, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, and L602W.

11. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, 329, 330, 331 and 332.

12. The prime editing system of claim 11, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, E329P, K330G, G331T and E332C.

13. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 305, 312, 329, 330, 331, 332, and 602.

14. The prime editing system of claim 13, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, T305K, W312F, E329P, K330G, G331T, E332C, and L602W.

15. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 222, 305, 312, and 602.

16. The prime editing system of claim 15, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, V222A, T305K, W312F, and L602W.

17. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 63, 199, 222, 305, 312, and 602.

18. The prime editing system of claim 17, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions Y63R, D199N, V222A, T305K, W312F, and L602W.

19. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 199, 222, 305, 312, 408 and 602.

20. The prime editing system of claim 19, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions D199N, V222A, T305K, W312F, C408R, and L602W.

21. The prime editing system of claim 6, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions at positions 63, 199, 222, 305, 312, 408 and 602.

22. The prime editing system of claim 13, wherein the functional variant of the PERV reverse transcriptase comprises amino acid substitutions Y63R, D199N, V222A, T305K, W312F, C408R, and L602W.

23. The prime editing system of any one of claims 1-4, wherein the functional variant of the PERV reverse transcriptase comprises an amino acid sequence of one of SEQ ID NOs: 6-17 or 40-44.

24. The prime editing system of any one of claims 1 to 23, wherein in the fusion protein, the reverse transcriptase or a functional variant thereof is fused to a nucleocapsid protein (NC) at the N-terminus or the C-terminus directly or through a linker.

25. The prime editing system of claim 24, wherein the nucleocapsid protein (NC) is derived from PERV, preferably, the nucleocapsid protein and the reverse transcriptase are derived from the same type of PERV.

26. The prime editing system of claim 24 or 25, wherein the nucleocapsid protein comprises the amino acid sequence shown in one of SEQ ID NOs: 19 or 36-39.

27. The lead editing system of any one of claims 24-26, wherein the PERV reverse transcriptase or a functional variant thereof is fused to the nucleocapsid protein (NC) at the N-terminus directly or through a linker.

28. The lead editing system of any one of claims 1-27, wherein the CRISPR nuclease, such as CRISPR nickase, and the PERV reverse transcriptase or a functional variant thereof in the lead editing fusion protein are connected via a linker.

29. The lead editing system of any one of claims 1-28, wherein the CRISPR nickase is a Cas9 nickase, for example, the Cas9 nickase comprises the amino acid sequence shown in SEQ ID NO:

18.

30. The prime editing system of any one of claims 1-29, wherein the CRISPR nuclease, such as a CRISPR nickase, in the fusion protein is located at the N-terminus of the reverse transcriptase or a functional variant thereof.

31. The prime editing system of any one of claims 1-30, wherein the fusion protein further comprises a nuclear localization sequence (NLS).

32. The prime editing system of any one of claims 1-31, wherein the fusion protein may further include a selectable marker protein linked directly or via a self-cleavable peptide.

33. The prime editing system of claim 32, wherein the self-cleaving peptide is a 2A polypeptide and the selectable marker protein is a Puro-R protein.

34. The prime editing system of claim 1, wherein the fusion protein comprises an amino acid sequence shown in one of SEQ ID NOs: 22-34 or SEQ ID NOs: 45-49.

35. The lead editing system of any one of claims 1-34, wherein the at least one pegRNA is capable of forming a complex with the fusion protein and targeting the fusion protein to a target sequence in the genome, resulting in a nick within the target sequence.

36. The lead editing system of any one of claims 1 to 35, wherein the lead sequence in at least one pegRNA is configured to have sufficient sequence identity with the target sequence, preferably 100% identity, so that it can bind to the complementary strand of the target sequence through base pairing to achieve sequence-specific targeting.

37. The lead editing system of any one of claims 1-36, wherein the scaffold sequence is shown in SEQ ID NO:

21.

38. The prime editing system of any one of claims 1 to 37, wherein the primer binding sequence is set to be complementary to at least a portion of the target sequence, preferably, the primer binding sequence is complementary to at least a portion of the 3' free single strand caused by the nick, in particular, complementary to the nucleotide sequence at the 3' end of the 3' free single strand.

39. The lead editing system of any one of claims 1 to 38, wherein The RT template sequence is set to correspond to the sequence downstream of the nick and contains the desired modification, which includes substitution, deletion and / or addition of one or more nucleotides.

40. The lead editing system of any one of claims 1-39, further comprising a nicking gRNA and / or an expression construct containing a nucleotide sequence encoding the nicking gRNA, wherein the nicking gRNA comprises a leader sequence and a scaffold sequence, wherein the leader sequence is configured to have sufficient sequence identity with a target sequence in the genome so as to be able to target the fusion protein to the target sequence and cause a nick within the target sequence, wherein the target sequence of the nicking gRNA and the target sequence of the pegRNA are located on opposite strands of the genomic DNA, and the nick induced by the nicking gRNA and the nick induced by the pegRNA are approximately 1 to approximately 300 nucleotides apart.

41. The lead editing system of any one of claims 1-40, comprising at least one pair of pegRNAs and / or an expression construct comprising a nucleotide sequence encoding the at least one pair of pegRNAs.

42. The lead editing system of claim 41, wherein the two pegRNAs in the pegRNA pair are configured to target different target sequences on the same strand of genomic DNA, or the two pegRNAs in the pegRNA pair are configured to target target sequences on different strands of genomic DNA.

43. The lead editing system of any one of claims 41-42, wherein the two pegRNAs in the pegRNA pair are configured to introduce the same desired modification. The lead editing system of any one of 44. claims 1-43, wherein the pegRNA comprises the Csy4 recognition sequence of the brachymemma shown in SEQ ID NO:51 at 3' end.

45. A method for producing genetically modified cells, comprising introducing the lead editing system of any one of claims 1-44 into at least one of the cells, thereby resulting in modification of the genomic sequence of the at least one cell.

46. ​​The method of claim 45, wherein the lead editing system is introduced into the cell in the presence of one or more small molecule compounds selected from RS-1, nocodazole and trichostatin A (TSA), preferably RS-1 and nocodazole; or After the lead editing system is introduced into the cells, the cells are treated with one or more small molecule compounds selected from RS-1, nocodazole and trichostatin A (TSA) (preferably RS-1 and nocodazole), for example, the cells are cultured in a culture medium containing the one or more small molecule cyclic compounds (preferably RS-1 and nocodazole).

47. The method of claim 45 or 46, wherein the cell is from a mammal, such as a human, mouse, rat, monkey, dog, pig, sheep, cow, cat.

Citation Information

Patent Citations

  • Novel gene editing system and related vector and method

    CN113549648A

  • Pilot editing system and gene editing method

    CN116396952A

  • Pilot editing system and application thereof

    CN117720672A

  • Guide editing system based on circular RNA

    CN118995701A

  • Compounds for increasing genome editing efficiency

    EP3489357A1

Cited By

  • Construction method of Alzheimer's disease model pig based on endogenous multi-gene editing

    CN120536504A

  • Novel reverse transcriptase XRT1 and application thereof in guiding editing

    CN122503350A

  • Novel reverse transcriptase xrt1 and its use in prime editing

    CN122503350B